# scientific reports

Check for updates

# **OPEN** Effectiveness of bowel preparation innovative technology instructions (BPITIs) on clinical outcomes among patients undergoing colonoscopy: a systematic review and meta-analysis

Parichat Wonggom<sup>1</sup>, Siwanon Rattanakanokchai<sup>2</sup> & Orathai Suebkinorn<sup>1</sup>

To evaluate the effectiveness of bowel preparation innovative technology instructions (BPITIs) among patients undergoing colonoscopy. We searched PubMed, MEDLINE, CINAHL, CENTRAL, Scopus, Web of Science, LILACS, ClinicalTrials.gov, and Google Scholar for randomised controlled trials (RCTs) and cluster-RCTs from inception to February 28, 2022. The Cochrane risk of bias (RoB) tool and GRADE were used to assess RoB and certainty of evidence, respectively. Meta-analyses with random-effects model were used for analysis. This review included 47 RCTs (84 records). Seven BPITIs were found among included studies: (1) mobile apps, (2) VDO stream from personal devices, (3) VDO stream from a hospital device, (4) SMS re-education, (5) telephone re-education, (6) computer-based education, and (7) web-based education. The findings demonstrate that BPITIs have a slight impact on adherence to overall instructions (RR 1.20, 95% CI 1.13–1.28; moderate-certainty evidence), adequate bowel preparation (RR 1.10, 95% CI 1.07–1.13; low-certainty evidence), and quality of bowel preparation score (SMD 0.42, 95% CI 0.33–0.52; low-certainty evidence) compared to routine care. BPITIs may enhance the clinical outcomes. Due to the low-certainty evidence and heterogeneity of the included studies, the findings should be interpreted cautiously. Well-designed and reported RCTs are required to confirm the findings.

# PROSPERO registration number: CRD42021217846.

Colorectal cancer (CRC) is a major global health problem. According to the International Agency for Research on Cancer, CRC accounts for approximately 1.9 million new cases and more than 900,000 deaths each year<sup>1</sup>. CRC ranks as the third most cancer, next to breast and lung cancer, and the second leading cause of cancer-related deaths<sup>2,3</sup>. In addition, the incidence of CRC tends to increase in adults under the age of 50, which is defined as an early-onset CRC (EOCRC)<sup>4</sup>. Several studies have demonstrated that colonoscopy screening can prevent CRC incidence and mortality by detecting and removing precancerous lesions<sup>5,6</sup>. Therefore, a high-quality colonoscopy is required to achieve the desired screening benefit.

Adequate bowel preparation is essential for the success of a colonoscopy to visualize the colonic mucosa<sup>6,7</sup>. However, several studies indicate inadequate bowel preparations occurred in approximately 18–35%<sup>8</sup>. Inadequate bowel preparations lead to unsuccessful colonoscopy and negative consequences, such as prolonged colonoscopy time, decreased cecal intubation rates, decreased pathological lesions detection rates, required early repeat colonoscopy, and increased overall treatment costs<sup>5,9</sup>. Certain factors associated with inadequate bowel preparation include advanced age, male gender, inpatient status, chronic diseases (e.g., diabetes mellitus, hypertension, cirrhosis, and stroke), constipation, and narcotic and tricyclic antidepressant use<sup>8</sup>. Furthermore,

<sup>1</sup>Department of Adult Nursing, Faculty of Nursing, Khon Kaen University, Khon Kaen 40002, Thailand. <sup>2</sup>Department of Epidemiology and Biostatistics, Faculty of Public Health, Khon Kaen University, Khon Kaen 40002, Thailand. <sup>⊠</sup>email: oratsu@kku.ac.th

a previous history of bowel preparation failure and non-adherence to bowel preparation instructions lead to sub-optimal bowel preparation<sup>10</sup>.

Numerous factors are associated with adequate bowel preparation, particularly those relating to healthcare providers and patients<sup>11</sup>. Healthcare providers are responsible for effectively educating patients on the bowel preparation process and emphasizing the significance of adequate bowel preparation. Patients undergoing colonoscopy must adhere to bowel preparation instructions, including dietary restrictions and proper purgative administration. Bowel preparation processes are complex and challenging for patients, particularly those undergoing their first colonoscopy<sup>11</sup>. Traditionally, healthcare professionals provide bowel preparation information with verbal or written instructions prior to colonoscopy day. These traditional education methods are unlikely enough to enable patients to comply with the bowel preparation instructions accurately, resulting in poor bowel cleansing, which negatively impacts the colonoscopy<sup>12</sup>. Therefore, strategies to optimize bowel preparation are critical.

Various innovative technology platforms have been used to enhance the quality of bowel preparation, such as smartphone-based, computer-based, and virtual reality videos. These technological platforms provide comprehensive instructions for bowel preparation in a timely manner, with a design that is both accessible and attractive. In addition, some technological platforms have a reminder function that assists patients in precisely following instructions and a communication function that enables patients to communicate directly with health-care providers if they require additional information. Evidence revealed that these pre-colonoscopy educational programs could improve bowel cleanliness, adenoma and polyp detection rates, and adherence to bowel preparation instructions<sup>12,13</sup>. Therefore, innovative technology platforms have seemed to be widely utilised in bowel preparation before colonoscopy<sup>14</sup>.

Two systematic reviews were conducted to assess the effects of innovative technology education platforms on the quality of bowel preparation<sup>14,15</sup>. However, only the effects of mobile health (mHealth) technologies on colonoscopy preparation outcomes were evaluated in one review. Other innovative technology platforms, such as computer-based, virtual reality videos, and social media platforms, appear to improve bowel cleanliness<sup>13,16,17</sup>. Moreover, the findings of these two reviews were based on trials published prior to 2020. In recent years, further trials evaluating the effects of innovative technology instructions for bowel preparation have been published. We, therefore, conducted this systematic review to update the evidence regarding the effectiveness of bowel preparation innovative technology instructions (BPITIs) among patients undergoing colonoscopy by evaluating all available BPITIs.

# Methods

We conducted this systematic review following the Cochrane Handbook for Systematic Reviews of Interventions<sup>18</sup>. This systematic review was reported in accordance with the reporting guidance provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA 2020) statement (Supplementary S1)<sup>19</sup>. The protocol of this systematic review can be found in the Prospective Register of Systematic Reviews (PROSPERO) (https://www.crd.york.ac.uk/prospero) with the registration number CRD42021217846.

**Eligibility criteria.** We included individual randomised controlled trials (RCTs) and cluster randomised controlled trials (cluster RCTs) evaluating the effects of bowel preparation innovative technology instructions (BPITIs) in this review regardless of the language of publication, publication status, or year of publication. We included trials that included males and females aged 18 years and over undergoing colonoscopy. The BPITIs can be any bowel preparation interventions developed by using innovative technology to deliver bowel preparation information for patients to prepare their bowel for colonoscopy, such as mobile applications, telehealth, virtual social networks, or computer-based program. These interventions should be delivered to participants before they start their colonoscopy. Supplementary S2 outlines the definition of BPITIs that we found and grouped in our review. Comparators can be no intervention, usual care, or another bowel preparation innovative technology instruction(s).

**Types of outcome measures.** Primary outcomes were adherence to instructions and bowel cleansing. Adherence to instructions can be assessed by adherence score (AS) and any validated instruments developed by a research team to use these instruments for their research. For bowel cleansing, this outcome should be assessed by the following measures: (1) the Aronchick scale, (2) the Ottawa Bowel Preparation Scale (OBPS), (3) the Boston Bowel Preparation Scale (BBPS), (4) the Chicago Bowel Preparation Scale, (5) the Harefield Cleansing Scale (HCS), (6) the Universal Preparation Assessment Scale (UPAS), and (7) any bowel preparation scales developed by a research team to use these scales for their research. The types of these two primary outcomes can be either dichotomous or continuous outcomes.

For secondary outcomes, we planned to evaluate the effects of BPITIs on polyp detection rates as assessed by the number of patients with polyps, and patient satisfaction as assessed by a numeric rating scale (NRS), a visual analogue scale (VAS), or a validated questionnaire which was developed by the research team who conducted that trial.

**Information sources.** A systematic literature search was performed using the major electronic databases, including (1) PubMed, (2) MEDLINE (via Ovid), (3) CINAHL (via EBSCO), (4) Cochrane Central Register of Controlled Trials (CENTRAL), (5) Scopus, (6) ISI Web of Science, and (7) LILACS. We also reviewed reference lists of included trials and contacted trial authors to obtain additional data if necessary. In addition, we searched for ongoing studies in ClinicalTrials.gov, as well as unpublished studies in the Open Grey database. To ensure

comprehensive searches, we searched for potential studies on Google Scholar, focusing on the first 50 records  $identified^{20}$ .

**Search strategy.** We systematically searched to identify all possible published and unpublished studies in the databases as mentioned above from their inception until February 28, 2022. The search strategy was developed using text words and medical subject headings (MeSH) according to the PICO model. Boolean operators including "AND" and "OR" were used to combine search terms for each PICO model or across PICO models, which were "colonoscope", "bowel preparation", "educational technologies", and "randomised controlled trial". Supplementary S3 presents the complete search strategy for each database.

**Selection process.** All records retrieved from each database were imported into Mendeley software to remove duplicate records. After duplicate records were removed, we then uploaded the records into Rayyan software. This online platform allows systematic reviewers to screen studies independently for titles and abstracts and full-text screening. At least two reviewers (PW, OS, and SR) independently screened titles and abstracts and full texts. Any disagreements between the two reviewers, either at the titles and abstracts screening stage, were resolved by discussion; if required, the third reviewer was asked to reach a consensus. Studies published in a language other than Thai and English were translated into English using Google Translate. For any unclear data, the first or corresponding authors of the original study were contacted and requested to confirm unclear data. We presented the results of the search and selection process in the PRISMA flow diagram (Fig. 1).

**Data collection process.** One of the review authors (SR) developed a data extraction form in Microsoft Access designed explicitly for this review. The form was piloted by all review authors before being implemented. At least two reviewers (PW, OS, and SR) independently extracted information from eligible trials using the agreed data extraction form. One of the reviewers (SR) checked for differences in the short text field data, drop-down list data, and numeric data extracted from two review authors using STATA software version 15.1. Any disagreements between two reviewers were resolved by discussion; if required, the third reviewer was asked to reach a consensus. We contacted the authors of the original study to request for confirm unclear or additional information. Plot digitizer software was used to extract information from graphs if the eligible trials did not provide numeric information for us to perform a meta-analysis in their report.

**Study risk of bias assessment.** The Cochrane risk-of-bias tool version 1.0 for randomised controlled trials was used to assess the risk of bias among the eligible trials<sup>21</sup>. At least two reviewers (PW, OS, and SR)




Figure 1. PRISMA diagram.

independently evaluated the risk of bias. Each included trial was assessed the risk of bias based on the following domains: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, and (6) selective reporting. We justified each risk of bias domain as "low risk of bias", "high risk of bias", and "unclear risk of bias". Due to the nature of the trials evaluating the effects of an educational intervention for bowel preparation, participants and personnel could not be blinded. Therefore, all included studies were rated as having a high risk of bias for this domain, and this domain was not used to calculate the overall risk of bias for included studies. For the overall risk of bias, included studies were classified as high risk of bias if at least one RoB domain was classified as high risk of bias for any domain, and as low risk of bias if all RoB domains were classified as low risk of bias. Any discrepancies between the two reviewers were addressed through discussion, and if necessary, a third reviewer was invited to reach a conclusion.

**Effect measures.** Relative risk (RR) was computed and presented for dichotomous outcomes, including adherence to instructions (overall, purgative intake, and dietary restrictions), adequate bowel preparation, polyp detection, and patient satisfaction. For continuous outcomes, mean difference (MD) and standardised mean difference (SMD) were computed and presented for outcomes that were measured using the same unit of measurement across trials and using different measurements across trials, respectively. The outcomes that were measured using different measurements included adherence to instructions (overall, purgative intake, and dietary restrictions), bowel preparation quality score, and satisfaction score. To interpret the SMD results, we followed Cohen's effect sizes guideline outlined in the Cochrane handbook<sup>22</sup>. The following details are the SMD interpretation meaning that we used: (1) SMD less than 0.40 = small effect, (2) SMD greater than 0.40 and less than 0.69 = medium effect, and (3) SMD 0.70 or greater = large effect. Adjusted Odds Ratio (OR<sub>adj</sub>) and adjusted coefficient (Coef<sub>adj</sub>) were estimated and presented for adequate bowel preparation and bowel preparation quality score outcomes if the included trials provided effect estimates that were adjusted for confounding factors by statistical modelling. Separate analyses and presentations were made for both unadjusted and adjusted effect estimates.

We found that some of the included trials used the Ottawa Bowel Preparation Scale (OBPS) and the Aronchick Scale (AC) to measure bowel preparation quality. The directional scale of these two measurement tools differs from the other scales; a lower score means adequate bowel preparation for OBPS and AC, while a higher score means adequate bowel preparation for the other standardised bowel preparation scales. To make every tool have the same directional scale, we multiplied the mean values of trials that used (1) OBPS, (2) AC, and (3) bowel preparation scales that a lower score means adequate bowel preparation by  $-1^{23}$ .

**Synthesis methods.** Study characteristics were presented in tabular format. We performed pair-wise meta-analyses using the random-effects model with the inverse variance weighting approach for all primary and secondary outcomes with at least two available trials<sup>24</sup>. We performed analyses on an intention-to-treat basis as far as possible. The results of random-effects models were presented in forest plots as the average treatment effects with 95% confidence intervals (CIs). RevMan software version 5.4.1 was used to perform meta-analysis for all analyses<sup>25</sup>.

For trials reporting zero events in one intervention arm, we added a correction factor of 0.5 into all cells of the study results to estimate the effect sizes. Trials with zero events in all intervention arms were removed from the meta-analysis. For trials that did not provide standard errors (SEs), we calculated SEs based on the width of CIs. If an included study reported treatment effects as a median and range or interquartile range, we computed the mean and standard deviation (SD) from these values using methods described by Wan and colleagues<sup>26</sup>.

We found trials with multiple intervention groups. To avoid double counting participants in the shared group (aka control group) and to address a correlation between the estimated intervention effects from multiple comparisons, we split the shared group into two or more groups depending on the number of intervention groups and adjusted its sample size by the number of comparisons. We then included two or more comparisons in meta-analyses<sup>27</sup>. For dichotomous outcomes, the number of events and the total number of participants were adjusted. For continuous outcomes, only the total number of participants was adjusted, while the means and standard deviations were unchanged.

We investigated statistical heterogeneity among trials included in each meta-analysis using visual inspection and statistical approaches. For the visual inspection approach, we considered the poor overlap of 95% CIs of the results of included trials in a forest plot. Statistical heterogeneity was identified if the I<sup>2</sup> statistic value was greater than 75% and the *p* value from the Cochrane Q test was less than 0.10.

**Subgroup analysis and sensitivity analysis.** We explored potential sources of heterogeneity for all primary outcomes by performing a subgroup analysis. Subgroup analyses were performed according to the following potential effect modifiers: (1) types of intervention and (2) types of bowel preparation scale. Sensitivity analyses were performed to assess the robustness of the findings by removing trials with the following factors: (1) unclear or high risk of overall risk of bias and (2) abstract only available.

**Publication bias assessment.** A funnel plot was generated to assess publication bias for all primary outcomes if ten or more studies were included in a meta-analysis.

**Certainty of evidence.** The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence for all primary outcomes across five domains:

(1) risk of bias in the included studies, (2) inconsistency of results among included studies, (3) imprecision in the effect estimate, (4) indirectness of evidence, and (5) publication bias. The overall certainty of each piece of evidence was assessed as "very low", "low", "moderate", or "high". Two review authors (OS and SR) independently assessed the certainty of evidence; these results were then reviewed by the third review author (PW). All reviewers reached a consensus regarding the level of overall evidence certainty. GRADEPro GDT was utilised to construct the Summary of Findings (SoF) table<sup>28</sup>. Figure 2 illustrates a summary of findings table for primary outcomes. Supplemental S16 provides full details for the summary of findings table.

# Results

**Study selection.** Figure 1 presents the PRISMA flow diagram for study selection. A systematic literature search identified 741 records from the major electronic databases, ClinicalTrials.gov, and Google Scholar. After removing 292 duplicate records, 449 records were independently screened by reviewing their titles and abstracts. 332 records were excluded because they did not meet the eligibility criteria, leaving 117 potential records for full-text reviews. 84 records of 47 studies met the eligibility criteria and were included in the quantitative synthesis<sup>12,16,17,29–72</sup>. (Supplementary S4) 18 records were excluded because of wrong study design (9 records), duplicate records (3 records), wrong publication type (2 records), wrong intervention (3 records), and untrustworthiness findings (1 record). Supplementary S5 shows the list of excluded studies with their exclusion reasons. 15 ongoing studies evaluating the effects of bowel preparation innovative technology instructions were identified. (Supplementary S6).

**Characteristics of include studies.** Supplementary S7 summarises information on the characteristics of the included studies. Of the 47 included studies, all studies were individual randomised controlled trials. All trials were included in the quantitative analyses. Eight studies (17.0%) were reported in conference proceedings, with only abstracts being available<sup>30,32,33,41,44,52,55,65</sup>. Publication dates ranged from 2001 and 2022. We found six trials (10.4%) with multiple intervention groups; these trials were included in more than one comparison<sup>39,41,45,51,56,69</sup>. The included studies were conducted in 13 countries: the United States (12 studies)<sup>32,36,40,49,50,55,57-59,62,64,67</sup>, China (10 studies)<sup>16,35,37,46,47,52,63,69,71,72</sup>, the Republic of Korea (9 studies)<sup>31,38,39,41,44,45,51,53,54</sup>, Spain (three studies)<sup>29,48,60</sup>, Hong Kong<sup>42,43</sup>, Germany<sup>12,68</sup>, and the Netherlands<sup>17,66</sup> (two studies each), and Australia<sup>56</sup>, Canada<sup>65</sup>, Denmark<sup>34</sup>, Lebanon<sup>61</sup>, Taiwan<sup>70</sup>, and the United Kingdom<sup>30</sup> (one study each). One study did not report the study setting<sup>33</sup> (Supplementary S8).

A variety of interventions were found in the included studies. To address this issue, we attempted to categorise the interventions into seven categories based on their main characteristics. Following are the seven types of interventions that we classified: 1) mobile apps, 2) VDO stream from personal devices, 3) short message services (SMS) re-education, 4) VDO stream from an on-site hospital device, 5) telephone re-education, 6) computerbased education, and 7) web-based education. The definition of each intervention can be found in Supplementary S2. All included studies compared these bowel preparation innovative technology instructions with routine care. The routine care consisted of bowel preparation instructions that were delivered by well-trained healthcare providers (physicians or nurses) with printed materials such as leaflets or booklets. Supplementary S9 presents contents of bowel preparation provided in each included study.

Among the 47 included studies, 45 studies (95.7%) reported at least one of the primary outcomes<sup>12,16,17,29-55,57-61,63-72</sup>. The two most common outcomes were adequate bowel preparation rate and quality of bowel preparation score outcomes, which were investigated in 37 trials (78.7%)<sup>12,16,17,29,30,32,35-44,46-50,52-5</sup> 4,57,59-61,63-70,72</sup> and 34 trials (72.3%)<sup>12,16,17,31-35,38-41,43-48,51-55,57-59,61,64,66-69,71,72</sup>, respectively. (Supplementary S10)

Outcomes			Summary es	stimates				GRAD	DE		Certainty of evidence	
	k	n	Effect size	(95% CI)	l <sup>2</sup>	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	-	
Adherence with instruction												
Binary outcomes												
Overall instruction	8	3,649	RR 1.20	(1.13 to 1.28)	76%						⊕⊕⊕⊙	Moderate
Purgative intake	9	3,840	RR 1.05	(1.02 to 1.07)	52%						⊕⊕⊕⊙	Moderate
Dietary restrictions	10	4,859	RR 1.10	(1.05 to 1.15)	73%						⊕⊕⊕⊙	Moderate
Continuous outcomes												
Overall instruction	1	198	MD 0.97	(0.61 to 1.33)	-						⊕⊕○ ○	Low
Purgative intake	2	370	SMD 0.80	(0.39 to 1.21)	49%						<b>0</b> 00	Very low
Dietary restrictions	2	370	SMD 0.99	(0.35 to 1.63)	76%						<b>0</b> 00	Very low
Adequate bowel preparation	37	18,284	RR 1.10	(1.07 to 1.13)	78%						⊕⊕○ ○	Low
Quality of bowel preparation score	31	11,724	SMD 0.42	(0.33 to 0.52)	84%						<b>0000</b>	Low

**Figure 2.** Summary of findings table for primary outcomes. ■, downgrade one level for each GRADE domain; ⊕, level of certainty of evidence; k, number of studies; n, number of participants; RR, risk ratio; MD, mean difference; SMD, standardized mean difference; CI, confidence interval.

.....

Various validated bowel preparation scales were used to evaluate the quality of bowel preparation in the included studies. We identified 26 included studies using the Boston Bowel Preparation Scale (BBPS)<sup>12,17,29–33,35,37,39–41,4</sup> <sup>4,45,55,59,60,63–69,71,72</sup>, 10 using the Ottawa Bowel Preparation Scale (OBPS)<sup>16,38,46,47,51–54,57,58</sup>, five using the Aronchick scale (AC)<sup>36,42,49,61,70</sup>, one using the Harefield Cleansing Scale (HCS)<sup>48</sup>, and one using the AC and BBPS as measuring scales<sup>43</sup>. Two studies did not report the name of the bowel preparation scale used to evaluate bowel preparation quality in their trial report<sup>34,50</sup>. These 45 included studies quantified and analysed the quality of bowel preparation as either binary outcome (adequate bowel preparation rate) or continuous outcome (quality of bowel preparation score).

The included studies reported the following three outcomes for adherence to instructions: (1) adherence to overall instruction, (2) adherence to purgative intake, and (3) adherence to dietary restrictions. These three adherence outcomes were quantified and analysed as either binary or continuous outcomes in the included studies. Among these trials, the authors of the original study developed and validated their own measurement scale to quantify the adherence to instruction outcomes among their participants.

**Risk of bias in studies.** A summary risk of bias for each included study is presented in Fig. 3. 23 studies (48.9%) were classified as having an unclear risk of bias for the overall risk of bias<sup>12,30,32–34,36,38,41,44,49,51,52,54,55,57,58,61,63,65–68,72</sup>, 11 studies (23.4%) as having a high risk of bias<sup>17,29,40,42,48,50,56,59,60,62,64</sup>, and 13 studies (27.7%) as having low risk of bias<sup>16,31,35,37,39,43,45–47,53,69–71</sup>.

# **Results of syntheses**

**Primary outcomes.** The primary outcomes were adherence to instructions and bowel preparation. The included studies reported three categories of adherence to instructions outcomes: 1) adherence to overall instruction, 2) adherence to purgative intake, and 3) adherence to dietary restrictions. The bowel preparation outcomes were presented as the rate of adequate bowel preparation and the quality of bowel preparation score as the following information.


**Adherence to instructions.** The meta-analyses and subgroup analyses by types of intervention for adherence to instructions outcomes are shown in Fig. 4, Table 1, and Supplementary S11.


Adherence to overall instruction. Bowel preparation innovative technology instructions (BPITIs) probably increase the rate of adherence to overall instruction slightly when compared to routine care (RR 1.20, 95% CI 1.13 to 1.28; 8 studies; 3649 participants; moderate-certainty evidence; Fig. 4A)<sup>16,35,37-39,47,61,72</sup>, although there was substantial heterogeneity for this outcome ( $I^2 = 76\%$ ; *p* value <0.001). Only one study (198 participants) reported adherence score to overall instruction<sup>71</sup>; this trial evaluated the effect of VDO stream from personal devices on this outcome. The evidence suggests that this intervention results in a slight increase in the adherence score to overall instruction (MD 0.97, 95% CI 0.61 to 1.33; low-certainty evidence; Fig. 4B). Subgroup analysis indicated no significant difference in the adherence rate to overall instruction outcome across the types of intervention (*p* value 0.35). However, the evidence of this subgroup analysis is very uncertain about the effect of VDO stream from personal devices on this outcome (RR 1.13, 95% CI 0.97 to 1.13; 2 studies; 430 participants; Supplementary S11B)<sup>38,39</sup>.


Adherence to purgative intake. The evidence suggests BPITIs result in a slight increase in the rate of adherence to purgative intake when compared to routine care (RR 1.05, 95% CI 1.02 to 1.07; 9 studies; 3840 participants; moderate-certainty evidence; Fig. 4C)<sup>12,16,29,37,45,47,54,61,69</sup>, although there was moderate heterogeneity for this outcome (I<sup>2</sup> = 52%; *p* value = 0.02). The same result was seen on the adherence score to purgative intake outcome, in which BPITIs may increase this outcome compared to routine care but the evidence is very uncertain (SMD 0.80, 95% CI 0.39 to 1.21; 2 studies; 370 participants; very low-certainty evidence; Fig. 4D)<sup>31,51</sup>. However, there was no serious heterogeneity for this outcome (I<sup>2</sup> = 49%; *p* value = 0.14). Subgroup analysis indicated that the type of intervention might make a difference in the adherence rate to purgative intake (*p* value = 0.009). Mobile apps (RR 1.08, 95% CI 1.03 to 1.13; 5 studies; 1838 participants; Supplementary S11C)<sup>12,16,37,61,69</sup> and SMS (RR 1.04, 95% CI 1.01 to 1.08; 3 studies; 658 participants; Supplementary S11C)<sup>45,54,69</sup> may increase the rate of adherence to purgative intake, but telephone re-education has little to no effect on this outcome (RR 1.01; 95% CI 0.99 to 1.03; 3 studies; 1344 participants; Supplementary S11C)<sup>29,45,47</sup>.

Adherence to dietary restrictions. BPITIs are likely to result in a slight increase in the rate of adherence to dietary restrictions compared to routine care (RR 1.10, 95% CI 1.05 to 1.15; 10 studies; 4859 participants; moderate-certainty evidence; Fig. 4E)<sup>12,16,29,37,45,47,54,61,69,72</sup>. Substantial statistical heterogeneity was noted for this outcome (I<sup>2</sup> = 73%; *p* value < 0.001). Two trials involving 370 participants reported the dietary restrictions adherence score. The result showed that BPITIs probably result in an increase in this outcome when compared to routine care but the evidence is very uncertain (SMD 0.99, 95% CI 0.35 to 1.63; 2 studies; 370 participants; very low-certainty evidence; Fig. 4F)<sup>31,51</sup>. The heterogeneity was not identified in this meta-analysis (I<sup>2</sup> = 0%; *p* value = 0.57). Subgroup analysis by types of intervention could not explain the source of heterogeneity for the rate of adherence to dietary restrictions outcome (*p* value = 0.38).

*Sensitivity analysis and publication bias assessment.* Sensitivity analyses that eliminated the trials with an unclear or high risk of overall risk of bias and trials that abstract only available did not alter the results of these outcomes (Table 2). Only the meta-analysis of the rate of adherence to dietary restrictions outcome has a suf-







**Figure 4.** Effects of bowel preparation innovative technology interventions (BPITIs) on adherence with instructions for overall preparation, purgative intake, and diets. Telephone, telephone re-education; SMS, short message service; VDO hospital, video stream from an on-site hospital device; VDO personal devices, video stream from personal devices.

ficient number of studies to investigate for publication bias. The funnel plot for this outcome was symmetrical (Supplementary S15A).

**Bowel preparation.** Figure 5 presents the meta-analysis findings on (1) adequate bowel preparation rate and (2) quality of bowel preparation score. The findings of subgroup analyses by types of bowel preparation scale and types of intervention can also be found in Fig. 6, Table 1, and Supplementary S12-S13. Three included studies did not report the standard deviations (SDs) for both the intervention and comparison groups<sup>33,58,64</sup>. Therefore, these trials were not comprised in the quantitative analyses of the quality of bowel preparation score outcome.

*Rate of adequate bowel preparation.* The evidence suggests BPITIs result in a slight increase in the rate of adequate bowel preparation when compared to routine care (RR 1.10, 95% CI 1.07 to 1.13; 37 studies; 18,284 participants; low-certainty evidence; Fig. 5A)<sup>12,16,17,29,30,32,35–43,45–50,52–54,57,59–61,63–70,72</sup>, although there was substantial heterogeneity for this outcome (I<sup>2</sup> = 78%; *p* value < 0.001). Subgroup analysis revealed that the types of bowel preparation scale and treatment may have impacted the pooled effect of this outcome. For types of intervention, most interventions may increase this outcome slightly, except for computer-based education which has little to no impact on this outcome, but the evidence is very uncertain (RR 1.01, 95% CI 0.96 to 1.06; 2 studies; 1102 participants; Supplementary S12A)<sup>17,29</sup>. The finding of subgroup analysis by bowel preparation scale indicated that trials that used BBPS (RR 1.08, 95% CI 1.05 to 1.11; 21 studies; 10,619 participants; Fig. 6A)<sup>12,17,29,30,32,35,37,39–41,45,59,60,63–69,72</sup> and OBPS (RR 1.19, 95% CI 1.15 to 1.23; 8 studies; 3779 participants; Fig. 6A)<sup>16,38,46,47,52–54,57</sup> might result in a better in the rate of adequate bowel preparation.

Five included studies reported the adjusted odds ratio  $(OR_{adj})$  for the adequate bowel preparation outcome<sup>31,43,45,53,54</sup>. The evidence suggests BPITIs result in a large increase in the rate of adequate bowel preparation  $(OR_{adj} 2.92, 95\% \text{ CI } 1.82 \text{ to } 4.67; 5 \text{ studies; } I^2 = 60\%)$  (Table 3 and Supplementary S14A).

*Quality of bowel preparation score.* BPITIs may increase the quality of bowel preparation score slightly compared to routine care (SMD 0.42, 95% CI 0.33 to 0.52; 31 studies; 11,724 participants; low-certainty evidence; Fig. 5B)<sup>12,16,17,31,32,34,35,38-41,43-48,51-55,58,59,61,66-69,71,72</sup>. Substantial statistical heterogeneity was noted for this outcome (I<sup>2</sup> = 84%; *p* value < 0.001). Subgroup analysis also indicated that the types of bowel preparation scale and treatment may have impacted the pooled effect of this outcome. For types of intervention, most interventions

	Adherence to								
	Binary outcomes	\$		Continuous out	comes	1			
	Overall instruction	Purgative intake	Dietary restrictions	Overall instruction	Purgative intake	Dietary restrictions	Adequate bowel preparation	Quality of bowel preparation score	
Subgroups	RR (95% CI)	RR (95% CI)	RR (95% CI)	MD (95% CI)	SMD (95% CI)	SMD (95% CI)	RR (95% CI)	SMD (95% CI)	
Whole sample	1.20 (1.13 to 1.28)	1.05 (1.02 to 1.07)	1.10 (1.05 to 1.15)	0.97 (0.61 to 1.33)	0.80 (0.39 to 1.21)	0.99 (0.35 to 1.63)	1.10 (1.07 to 1.13)	0.42 (0.33 to 0.52)	
$I^2$	76%	52%	73%	-	49%	76%	78%	84%	
Studies	8	9	10	1	2	2	37	31	
Participants	3649	3840	4859	198	370	370	18,284	11,724	
Computer based education	No data	No data	No data	No data	No data	No data	1.01 (0.96 to 1.06)	-0.12 (-0.30 to 0.06)	
$I^2$							27%	-	
Studies							2	1	
Participants							1102	497	
Mobile apps	1.18 (1.09 to 1.29)	1.08 (1.03 to 1.13)	1.07 (1.04 to 1.11)	No data	No data	No data	1.11 (1.06 to 1.16)	0.43 (0.30 to 0.57)	
$I^2$	70%	45%	41%				74%	79%	
Studies	4	5	6				12	10	
Participants	2176	1838	2856				5394	4685	
SMS	No data	1.04 (1.01 to 1.08)	1.14 (1.05 to 1.24)	No data	No data	No data	1.08 (1.03 to 1.13)	0.39 (0.20 to 0.59)	
$I^2$		0%	0%				68%	69%	
Studies		3	3				9	6	
Participants		658	658				5037	1499	
Telephone	1.27 (1.11 to 1.45)	1.01 (0.99 to 1.03)	1.13 (0.93 to 1.37)	No data	No data	No data	1.10 (1.03 to 1.18)	0.66 (0.53 to 0.78)	
$I^2$	56%	0%	93%				69%	0%	
Studies	2	3	3				5	4	
Participants	697	1344	1345				2445	1035	
VDO hospital	1.37 (1.14 to 1.64)	No data	No data	No data	1.28 (0.59 to 1.97)	1.23 (0.54 to 1.92)	1.21 (1.08 to 1.34)	0.41 (-0.08 to 0.91)	
$I^2$	-				-	-	39%	92%	
Studies	1				1	1	4	4	
Participants	346				44	44	1020	1028	
VDO personal devices	1.13 (0.97 to 1.33)	No data	No data	No data	0.60 (0.38 to 0.83)	0.91 (0.03 to 1.79)	1.09 (1.02 to 1.18)	0.42 (0.23 to 0.61)	
$I^2$	-				0%	82%	83%	83%	
Studies	2				2	2	8	12	
Participants	430				326	326	2836	3330	
Web-based educa- tion	No data	No data	No data	No data	No data	No data	1.27 (1.02 to 1.58)	No data	
$I^2$							-		
Studies							1		
Participants							188		

**Table 1.** Subgroup analyses of the effects of bowel preparation innovative technology interventions (BPITIs)on all primary outcomes when compared with routine care by types of bowel preparation intervention.Significant values are in bold.

may improve this outcome slightly, except for computer-based education (SMD -0.12, 95% CI -0.30 to 0.06; 1 study; 497 participants; Supplementary S12B)<sup>17</sup> and VDO stream from an on-site hospital device (SMD 0.41, 95% CI -0.08 to 0.91; 4 studies; 1028 participants; Supplementary S12B)<sup>34,35,46,51</sup> which have little to no effect on this outcome, but the evidence is very uncertain. The finding of subgroup analysis by types of bowel preparation scale indicated that trials that used BBPS (MD 0.60, 95% CI 0.42 to 0.77; 19 studies; 7357 participants; Supplementary S13)<sup>12,17,31,32,35,39–41,43–45,55,59,66–69,71,72</sup> and OBPS (MD -1.00, 95% CI -1.27 to -0.73; 10 studies; 3945 participants; Supplementary S13)<sup>16,38,46,47,51–54,58,61</sup> might result in a better in the quality of bowel preparation score.

One trial comparing the effect of SMS and routine care on the quality of bowel preparation score reported the adjusted coefficient ( $coef_{adj}$ ) for this outcome<sup>68</sup>. The confounding factor that was adjusted in this trial was gender. The evidence suggests SMS might improve this outcome slightly ( $coef_{adj}$  0.82, 95% CI 0.50 to 1.14; 1 study) (Table 3).

	Adherence to								
	Binary outcomes			Continuous outo	comes	_			
Sensitivity	Overall instruction Purgative intake		Dietary restrictions	Overall instruction	Purgative intake	Dietary restrictions	Adequate bowel preparation	Quality of bowel preparation score	
analyses	RR (95% CI)	RR (95% CI)	RR (95% CI)	MD (95% CI)	SMD (95% CI)	SMD (95% CI)	RR (95% CI)	SMD (95% CI)	
Whole sample	1.20 (1.13 to 1.28)	1.05 (1.02 to 1.07)	1.10 (1.05 to 1.15)	0.97 (0.61 to 1.33)	0.80 (0.39 to 1.21)	0.99 (0.35 to 1.63)	1.10 (1.07 to 1.13)	0.42 (0.33 to 0.52)	
$I^2$	76%	52%	73%	-	49%	76%	78%	84%	
Studies	9	11	12	1	3	3	37	31	
Participants	3649	3840	4859	198	370	370	18,284	11,724	
Studies with full-text	1.20 (1.13 to 1.28)	1.05 (1.02 to 1.07)	1.10 (1.05 to 1.15)	0.97 (0.61 to 1.33)	0.80 (0.39 to 1.21)	0.99 (0.35 to 1.63)	1.09 (1.06 to 1.12)	0.43 (0.33 to 0.54)	
$I^2$	76%	52%	73%	-	49%	76%	78%	85%	
Studies	9	11	12	1	3	3	32	26	
Participants	3649	3840	4859	198	370	370	15,914	10,020	
Studies with low RoB	1.28 (1.22 to 1.34)	1.07 (1.02 to 1.11)	1.16 (1.10 to 1.23)	0.97 (0.61 to 1.33)	0.60 (0.36 to 0.84)	0.57 (0.32 to 0.82)	1.17 (1.13 to 1.21)	0.57 (0.45 to 0.70)	
$I^2$	0%	54%	45%	-	-	-	21%	76%	
Studies	5	5	5	1	1	1	11	11	
Participants	2190	2319	2319	198	283	283	4892	4812	

**Table 2.** Sensitivity analyses by excluding abstract-only RCTs and unclear or high risk of bias RCTs. RR, risk ratio; MD, mean difference; SMD, standardized mean difference. Significant values are in bold.

.....

*Sensitivity analysis and publication bias assessment.* Sensitivity analyses revealed that the results of (1) adequate bowel preparation rate and (2) quality of bowel preparation score were not affected by removing the trials with an unclear or high risk of overall risk of bias and trials that abstract only available. (Table 2) The funnel plot for (1) the adequate bowel preparation rate and (2) the quality of bowel preparation score outcomes were somewhat asymmetrical, indicating some publication bias for these two outcomes (Supplementary S15B and S15C).

**Secondary outcomes.** Secondary outcomes include polyp detection rate and satisfaction, presented in the following section.

**Polyp detection rate.** The evidence suggests BPITIs increase polyp detection slightly when compared to routine care (RR 1.22, 95% CI 1.10 to 1.35; 20 studies; 7616 participants)<sup>16,29,30,32,35-39,41,44-47,52-54,66,67,69</sup>, although there was substantial heterogeneity for this outcome (I<sup>2</sup>=48%; *p* value=0.004) (Table 3 and Supplementary S14B).

**Satisfaction.** Two included studies only reported the rate of participants satisfied with intervention in the intervention group<sup>12,50</sup>. In addition, one trial did not report the SDs for the intervention and comparison groups for satisfaction score outcome<sup>64</sup>. Thus, these trials were not included in the quantitative analyses of (1) satisfaction with the intervention and (2) satisfaction score.

BPITIs may result in a slight increase in satisfaction with the intervention compared to routine care (RR 1.38, 95% CI 1.16 to 1.65; 5 studies; 1746 participants)<sup>45,58,60,62,69</sup>. Substantial statistical heterogeneity was noted for this outcome (I<sup>2</sup>=71%; *p* value < 0.001). The same result was seen in the satisfaction score outcome, in which BPITIs may increase this outcome compared to routine care (SMD 0.62, 95% CI 0.37 to 0.86; 10 studies; 2557 participants)<sup>31,35,39,48,51,60–62,66,70</sup> (Table 3 and Supplementary S14C and S14D).

# Discussion

This systematic review aimed to investigate the effectiveness of bowel preparation innovative technology instructions (BPITIs) for patients undergoing colonoscopy on clinical outcomes, including adherence to instructions, quality of bowel preparation, polyp detection, and participants' satisfaction. The findings of this systematic review indicate that the use of BPITIs for colonoscopy is likely associated with a slight improvement in all outcomes, as mentioned above. However, statistical heterogeneity was found to be moderate to high for all outcomes measured and the risk of publication bias was high. Different intervention types may have varying effects on adherence to purgative intake and the quality of bowel preparation. In addition, the quality of bowel preparation was also affected by the types of bowel preparation quality scale. Sensitivity analyses that excluded the trials with an unclear or high risk of overall risk of bias and trials with only an abstract available revealed no marked differences in the direction and magnitude of these associations.

We found two recent systematic reviews evaluating the effects of innovative technologies supporting colonoscopy preparation on patient and clinical outcomes; one review using traditional pair-wise meta-analysis<sup>14</sup> and the other using network meta-analysis<sup>15</sup>.

Bizri et al., 2021<sup>14</sup> compared Mobile health technologies (mHealth) with usual care. This review included 10 RCTs; all 10 studies were included in our review. They found that mHealth technologies are likely to improve

			<b>.</b> .				<b>B</b> : 1 = -:	
udy or Subgroup	BPIT Events		Routine Events		Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI	Risk of Bias ABCDE
varez-Gonzalez 2020	249	303	237	302	3.0%	1.05 [0.97, 1.13]	-	
rcher 2021	219	254	205	259	3.0%	1.09 [1.01, 1.18]	-	22022
earelly 2014 nen 2021	110 139	127 173	89 125	121 173	2.1% 2.2%	1.18 [1.04, 1.34] 1.11 [0.99, 1.25]		<b>? ? • • ?</b>
arg 2016	34	48	22	46	0.5%	1.48 [1.04, 2.11]	· · · · · · · · · · · · · · · · · · ·	22000
Jo 2020	112	145	84	148	1.5%	1.36 [1.15, 1.61]		- ăăăăăă
on 2019	71	140	60	141	0.8%	1.19 [0.93, 1.53]	+	
ng 2022 (Telephone vs Routine care)	83	101	40	53	1.4%	1.09 [0.91, 1.30]	+	
ng 2022 (VDO personal devices vs Routine care)	96	104	40	53	1.5%	1.22 [1.04, 1.44]		
ing 2016	318 412	387 424	266 403	383 406	2.9% 4.1%	1.18 [1.09, 1.28]	J <sup>+</sup>	
eswani 2020 m 2014 (SMS vs Routine care)	412	424	405	406	2.5%	0.98 [0.96, 1.00] 1.07 [0.96, 1.19]	1_	220022
m 2014 (Telephone vs Routine care)	125	126	59	68	2.7%	1.14 [1.04, 1.26]	-	22642
m 2021	687	983	665	1010	3.4%	1.06 [1.00, 1.13]	+	
m 2022	286	343	258	342	3.0%	1.11 [1.02, 1.19]	-	
e 2015 (SMS vs Routine care)	119	126	59	67	2.6%	1.07 [0.97, 1.18]	-	
e 2015 (Telephone vs Routine care)	124	125	59	67	2.8%	1.13 [1.03, 1.23] 1.16 [1.06, 1.27]	<u> </u>	
1 2014 1 2018	249 215	305 239	211 178	300 237	2.7% 2.9%	1.20 [1.10, 1.30]	1	
renzo-Zúñiga 2015	108	108	146	152	3.9%	1.04 [1.00, 1.08]		
ahmud 2019	16	19	30	31	1.1%	0.87 [0.71, 1.07]		
hmud 2021	226	242	238	262	3.6%	1.03 [0.98, 1.08]	+	
n 2015	318	387	266	383	2.9%	1.18 [1.09, 1.28]		??●●●
rk 2015	108	136	78	135	1.5%	1.37 [1.16, 1.63]		97999
rk 2016 lai 2018	229 30	250 56	198 15	252 48	3.1% 0.3%	1.17 [1.08, 1.26]	<u> </u>	
ai 2018 :e 2016	30	42	15 34	48 50	0.3%	1.71 [1.06, 2.79] 1.09 [0.84, 1.41]		
pane 2020	622	673	567	627	3.9%	1.02 [0.99, 1.06]	Ļ	
arara 2017	62	80	66	80	1.6%	0.94 [0.80, 1.10]	-+	
i 2019	188	200	174	200	3.3%	1.08 [1.01, 1.15]	+	
lonowicz 2022	540	608	470	538	3.7%	1.02 [0.97, 1.06]	t	••••
zuki 2018	106	227	82	223	1.0%	1.27 [1.02, 1.58]	<b>—</b>	22020
n der Zander 2021 Idbuijzen 2020	80	81	77	81	3.5%	1.04 [0.98, 1.10]	1	
ldhuijzen 2020 Ilker 2022	261 103	280 111	204 94	217 102	3.7% 3.0%	0.99 [0.95, 1.04] 1.01 [0.93, 1.09]	1 1	
lter 2019	225	248	199	247	3.1%	1.13 [1.05, 1.21]	-	
alter 2021	227	246	202	243	3.2%	1.11 [1.04, 1.19]	<del>+</del>	
ang 2019 (Mobile apps vs Routine care)	114	127	41	62	1.3%	1.36 [1.13, 1.64]		
ang 2019 (SMS vs Routine care)	111	128	41	62	1.3%	1.31 [1.08, 1.59]	<del></del>	
en 2020	51 489	70 542	36 469	70 534	0.7% 3.8%	1.42 [1.08, 1.85]	1	
ang 2018	409	542	+09	224	J.070	1.03 [0.98, 1.07]	ſ	
tal events terogeneity: Tau² = 0.00; Chi² = 180.68, df = 40	8011 0 (P < 0.00			owel	cleans		2 0.5 1 2 Durs [Routine care] Favours [BPITIs]	
tal events :terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 40	0 (P < 0.0	0001);	<sup>2</sup> = 78% ( <b>B) Bc</b>			Fave sing score	burs [Routine care] Favours [BPITIs]	-
<pre>tal (95% Cl) tal events terogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P &lt; 0.00001) idy or Subgroup</pre>	0 (P < 0.0) BPIT Mean S	0001);   	<sup>2</sup> = 78% ( <b>B) B(</b> Rou I Mean	tine care SD	e Total Wei	Fave Sing SCOTE Std. Mean Difference ght IV, Random, 95% CI	burs [Routine care] Favours [BPITIs] Std. Mean Difference IV, Random, 95% Cl	Risk of Bia A B C D E
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) <b>dy or Subgroup</b> k 2018	BPIT Mean S 7.53 1.3	0001);   Is D Tota 18 13	<sup>2</sup> = 78% ( <b>B) B(</b> Rou <u>I Mean</u> 9 6.29	tine care SD	e Fotal Wei 144 2	Favo Sting SCORE Std. Mean Difference ght IV, Random, 95% CI .9% 0.76 [0.52, 1.00]	Std. Mean Difference	Risk of Bia ABCDE
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> :k 2018 rely 2014	BPIT Mean S 7.53 1.3 6.99 1.8	0001);   Is D Tota (8 13)	<sup>2</sup> = 78% <b>B) BC</b> Rou <u>I Mean</u> 9 6.29 7 6.43	tine care SD	e Fotal Wei 144 2	Fave Sing SCOTE Std. Mean Difference ght IV, Random, 95% CI	Std. Mean Difference	Risk of Bia A B C D E
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> ix 2018 irrelly 2014 wman 2014 zer 2007	BPIT Mean S 7.53 1.3 6.99 1.8 8.01 -2.58 1	0001);   <b>Is</b> <b>D</b> Tota 18 13 13 13 13 13 13 13 13 13 13	2 = 78% (B) BC Rou <u>I Mean</u> 9 6.29 7 6.43 9 7.41 2 -2.33	tine care SD 1.83 2.54 0 0.74	5 Total Weig 144 2 121 2 171 90 2	Favo <b>Sing score</b> <b>Std. Mean Difference</b> <b>(V, Random, 95% CI</b> <b>(V, Random, 95% CI</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b> <b>(V)</b>	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) idy or Subgroup ik 2018 trelly 2014 wman 2014 zer 2007 en 2021	BelT           Mean         S           7.53         1.3           6.99         1.8           8.01         -2.58           7.61         1.6	0001);   <b>Is</b> <b>D</b> Tota <b>37</b> 12: 0 17: 3 7: 55 17:	<b>B) BC</b> <b>Rou</b> <b>I</b> <u>Mean</u> <b>6</b> 6.29 <b>7</b> 6.43 <b>9</b> 7.41 <b>2</b> -2.33 <b>3</b> 7.04	tine care SD 1.83 2.54 0 0.74 1.7	Total Wei 144 2 121 2 171 90 2 173 3	Favo Std. Mean Difference Std. Mean Difference 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 (0.13, 0.55]	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> k 2018 vrelly 2014 vman 2014 zer 2007 en 2021 n 2019	BPIT Mean S 7.53 1.3 6.99 1.8 8.01 -2.58 1	0001);   <b>b</b> <b>D</b> <b>Tota</b> 88 139 87 123 0 173 5 173 5 173 7 7 7 7 7 7 7 7 7 7 7 7 7	<b>(B) BC</b> <b>Rou</b> <b>I Mean</b> 9 6.29 7 6.43 9 7.41 2 -2.33 3 7.04 0 -5.97	tine care SD 1.83 2.54 0 0.74	Fotal         Wei           144         2           121         2           171         90           173         3           141         3	Favo Std. Mean Difference Mr. Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 6% -0.24 (-0.55, 0.07) 1% 0.34 (0.33, 0.55) 0% 0.28 (0.05, 0.52)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> k 2018 trelly 2014 wman 2014 zer 2007 an 2021 7019 g 2022 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care)	BPIT Mean S 7.53 1.3 6.99 1.8 8.01 -2.58 1 7.61 1.6 -5.47 1.7 7.3 1 7.7 1	<b>Is</b> <b>D</b> Tota <b>B</b> <b>D</b> Tota <b>38</b> 139 <b>37</b> 122 <b>0</b> 179 <b>3</b> <b>7</b> <b>55</b> 173 <b>7</b> <b>55</b> 173 <b>7</b> <b>16</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>17</b> <b>1</b>	<b>(B) BC</b> <b>Rou</b> <b>I Mean</b> 9 6.29 7 6.43 9 7.41 2 -2.33 3 7.04 0 -5.97 1 6.66 4 6.6	tine care SD - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1	Fotal         Weig           144         2           121         2           171         90           173         3           141         3           53         2           53         2	Fave Std. Mean Difference Iv. Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 0.24 (0.13, 0.55) 0.34 (0.13, 0.55) 0% 0.28 (0.05, 0.52) 15% 0.63 (0.29, 0.97) 5% 0.64 (0.49, 1.18)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> ik 2018 viral 2014 viral 2014 viral 2014 ar 2007 n 2019 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2021 (VDO personal devices vs Routine care)	BPIT Mean S 7.53 1.3 6.99 1.8 8.01 -2.58 1 7.61 1.6 -5.47 1.7 7.3 1 -3.6 1 -3.6 1	<b>b</b> <b>b</b> <b>b</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b>	<b>(B) BC</b> <b>Rou</b> <b>1 Mean</b> 9 6.29 7 6.43 9 7.41 2 -2.33 3 7.04 0 -5.97 1 6.66 4 6.66 7 -4.5	tine care SD 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.8	Fotal         Wei           144         2           121         2           171         2           173         3           144         3           53         2           53         2           383         3	Favo Stor, Mean Difference ght 1/V, Random, 95% CI 9% 0.26 [0.52, 1.00] 9% 0.25 [0.00, 0.50] Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 [0.13, 0.55] 5% 0.63 [0.29, 0.97] 5% 0.63 [0.29, 0.97] 5% 0.84 [0.49, 1.18] 3% 0.51 [0.37, 0.66]	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E 7 7 0 0 0 0 7 0 0 0 0 7 0
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 zer 2007 n 2019 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2026 g 2026 (VDO personal devices vs Routine care) g 2016 wanai 2020	BPITT Mean S 7.53 1.3 6.99 1.6 8.01 -2.58 1 7.61 1.6 -5.47 1.7 7.3 1 7.7 1 -3.6 1 8.7	bool); 1 bool);	<b>B B C</b> <b>B B C</b> <b>B C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b>	tine care SD 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.8 0.9	Fotal         Wein           144         2           121         2           171         90           173         3           141         3           53         2           53         2           383         3           406         3	Fave Std. Mean Difference Int. V. Random, 95% CI (V. Random, 95	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E ? 7 2 9 7 2 ? 7 9 9 9 9 ? 7 9 9 7 7 ? 9 9 9 7 ? 9
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k: 2018 rely 2014 wman 2014 zer 2007 n 2019 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2021 (VDO yersonal devices vs Routine care) g 2021 (VDO yersonal devices vs Routine care) g 2021 (DS vs Routine care)	BPIT Mean S 7.53 1.3 6.99 1.8 8.01 -2.58 1 7.61 1.6 -5.47 1.7 7.3 1 -3.6 1 -3.6 1	<b>b</b> <b>b</b> <b>b</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b>	<b>(B) BC</b> <b>Rou</b> <b>1 Mean</b> 9 6.29 7 6.43 9 7.41 2 -2.33 9 7.44 2 -2.33 9 7.45 4 4 -2.57 7 -4.5 4 8 -6.6 7 -4.5 4 8 -7.57 7 7 -6.51	tine care SD 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.8	Total         Wein           144         2           121         2           171         90         2           173         3           141         3         5           53         2         3           383         3         2           383         3         2           368         2         2	Favo Std. Mean Difference ght IV, Random, 95% CI 9% 0.76 [0.52, 1.00] 9% 0.25 [0.00, 0.50] Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 [0.13, 0.55] 0% 0.28 [0.50, 0.52] 5% 0.63 [0.29, 0.97] 5% 0.03 [0.04, 0.63] 4% 0.00 [-0.14, 0.14] 7% 0.33 [0.04, 0.63]	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E 7 7 0 0 0 0 7 0 0 0 0 7 0
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( tropole of the second	BPIT           Mean         S           7.53         1.3           6.99         1.8           7.61         1.6           -5.47         1.7           7.61         1.6           -5.47         1.7           7.61         1.6           7.61         1.6           7.61         1.6           7.61         1.8.7           6.76         1.2           7.09         1.3           8.15         0.5	boool); I boool); I boooli; I boooli; I boooli; I boooli; I boooli; I boooli; I boooli	<b>(B)</b> BC Rou <b>1 Mean</b> 9 6.29 7 6.43 9 7.41 2 -2.33 3 7.04 2 -2.33 3 7.04 4 6.6 7 -4.5 4 8.7 7 6.31 5 6.31 5 6.31 4 7.98	tine care SD - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.8 0.9 1.43 1.43 1.078	Total         Weii           144         2           121         2           171         90           173         3           141         3           53         2           383         3           406         3           68         2           333         3	Favo Sing Score Std. Mean Difference ght 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) % 0.25 (0.00, 0.50) Not estimable 0.24 (0.13, 0.55) 0.63 (0.29, 0.97) 5% 0.63 (0.29, 0.97) 5% 0.63 (0.29, 0.97) 5% 0.61 (0.49, 1.18) 3% 0.51 (0.37, 0.66) 1.04, 0.63 7% 0.62 (0.32, 0.92) 3% 0.17 (0.01, 0.32)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E 7 7 6 7 7 7 7 6 7 7 7 7 6 7 7 7 7 6 7 7 7 6 7 7 7 7 6 7 7 7 7 7 7 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( troverset = 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 zer 2007 n 2019 g 2022 (relephone vs Routine care) g 2022 (vDO personal devices vs Routine care) g 2020 (vDO personal devices vs Routine care) g 2021 (vDO personal devices vs Routine care) g 2014 (relephone vs Routine care) z 1014 (relephone vs Routine care) z 2015 (SMS vs Routine care)	BPIT           Mean         S           7.53         1.3           6.99         1.8           -2.58         1.7           7.61         1.6           -5.47         1.7           7.61         1.6           -5.46         1.7           7.7         1           -3.66         1           -3.7         1.3           8.7         6.7           6.7         1.2           6.7         1.2           6.8         1           6.8         1           6.8         1	b b b b b b b b b b b b b b b b b b b	<ul> <li>(B) BC</li> <li>Rou</li> <li>Rou<td>tine care <u>SD</u> 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.1 1.4 0.9 1.43 1.078 1.4</td><td>2 Total Weig 144 2 121 2 171 2 173 3 141 3 53 2 53 2 383 3 141 3 53 2 53 2 383 3 68 2 68 2 68 2 333 3 67 2</td><td>Fave Sing score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 (0.13, 0.55] 5% 0.63 (0.29, 0.97] 5% 0.63 (0.29, 0.97] 3% 0.61 (0.14, 0.14] 7% 0.33 (0.44, 0.63] 3% 0.17 (0.01, 0.32] 3% 0.17 (0.07, 0.67] 3%</td><td>Std. Mean Difference IV, Random, 95% CI</td><td>Risk of Bia A B ⊂ D E ? ? • • ? ? ? • • ? ? • • ? ? ? • • • •</td></li></ul>	tine care <u>SD</u> 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.1 1.4 0.9 1.43 1.078 1.4	2 Total Weig 144 2 121 2 171 2 173 3 141 3 53 2 53 2 383 3 141 3 53 2 53 2 383 3 68 2 68 2 68 2 333 3 67 2	Fave Sing score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 (0.13, 0.55] 5% 0.63 (0.29, 0.97] 5% 0.63 (0.29, 0.97] 3% 0.61 (0.14, 0.14] 7% 0.33 (0.44, 0.63] 3% 0.17 (0.01, 0.32] 3% 0.17 (0.07, 0.67] 3%	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B ⊂ D E ? ? • • ? ? ? • • ? ? • • ? ? ? • • • •
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 rely 2014 wman 2014 zer 2007 a 2021 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2021 2014 (SW s Routine care) 2014 (CHelephone vs Routine care) 2022 (JOI (Felephone vs Routine care) 2022 (JOI (SW so Routine care) 2022 (JOI (SW so Routine care) 2023 (JOI (SW so Routine care) 2015 (Telephone vs Routine care)	BPITT Mean S 7.53 1.3 6.99 1.8 8.01 -2.58 1 7.61 1.6 -5.47 1.7 7.3 1 -3.6 1 7.7 1 -3.6 1 7.7 1 -3.6 1 8.7 6.76 1.2 7.09 1.3 8.7 6.76 1.2 7.09 1.3 8.7 6.8 1 7.1 1	bool); I bool); I boo	<b>(B)</b> BC <b>Rou</b> <b>I</b> Mean 9 6.29 7 6.43 9 7.41 2 -2.33 3 7.04 0 -5.97 1 6.66 4 6.66 7 -4.5 4 8.7 7 6.31 5 6.31 5 6.3 5 6.3	tine care <u>SD</u> 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.8 0.9 1.43 1.43 1.43 1.4 1.4	Total         Wei           144         2           121         2           171         90           90         2           53         2           383         3           406         3           68         2           333         3           67         2	Favo Sing score Std. Mean Difference pht V. Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 0.24 (0.13, 0.55) 0.34 (0.13, 0.55) 0.50 (0.50, 0.52) 5% 0.63 (0.29, 0.97) 5% 0.84 (0.49, 1.13) 1% 0.05 (1.03, 0.66) 1.7% 0.33 (0.04, 0.63) 7% 0.37 (0.07, 0.67) 3% 0.7 (0.07, 0.67) 5% 0.84 (0.32, 0.93) 3% 0.7 (0.07, 0.67) 5% 0.53 (0.02, 0.63)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B ⊂ D E ? ? • • ? ? ? • • ? ? • • ? ? ? • • • •
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( troverall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 zer 2007 a 2021 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2021 (VDO personal devices vs Routine care) g 2014 (MS vs Routine care) a 2014 (Telephone vs Routine care) a 2015 (SMS vs Routine care) 2015 (SMS vs Routine care) 2016 (SMS vs Routine care) 2015 (SMS vs Routine care) 2016 (SMS vs Routine care) 2017 (SMS vs Routine care) 2018 (SMS vs Routine care)	BPIT           Mean         S           7.53         1.3           6.99         1.8           -2.58         1.7           7.61         1.6           -5.47         1.7           7.61         1.6           -5.46         1.7           7.7         1           -3.66         1           -3.7         1.3           8.7         6.7           6.7         1.2           6.7         1.2           6.8         1           6.8         1           6.8         1	boool); I boool); I boool)	<b>(B)</b> BC <b>Rou</b> <b>I</b> Mean 9 6.29 9 6.43 9 7.41 2 -2.33 3 7.04 0 -5.97 1 6.6 4 6.6 7 -4.5 4 8.7 7 -4.5 4 8.7 7 -4.5 4 8.7 5 6.31 5 6.3 5 6.3 1 7.24	tine care <u>SD</u> 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.1 1.4 0.9 1.43 1.078 1.4	Contail         Weig           144         2           121         2           171         90           90         2           173         3           141         3           53         2           383         3           406         3           68         2           333         3           67         2           71         2	Fave Sing score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 (0.13, 0.55] 5% 0.63 (0.29, 0.97] 5% 0.63 (0.29, 0.97] 3% 0.61 (0.14, 0.14] 7% 0.33 (0.44, 0.63] 3% 0.17 (0.01, 0.32] 3% 0.17 (0.07, 0.67] 3%	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B ⊂ D E 2 0 0 0 7 7 7 0 0 7 7 7 0 0 0 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( troverall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 zo10 2012 (Delphone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2021 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2021 (VDO personal devices vs Routine care) n 2014 (MS vs Routine care) n 2015 (SMS vs Routine care) 2016 (SMS vs Routine care) 2017 (SMS vs Routine care) 2018 (SMS vs Routine care) 2018 (SMS vs Routine care) 2018 (SMS vs Routine care) 2019 (SMS vs Routine care) 2010 (SMS vs Routine care) 2	BPIT           Mean         S           7.53         1.3           6.99         1.8           8.01         -2.58           -7.61         1.6           -5.47         1.7           7.61         1.6           7.73         1           -7.61         1.7           8.7         6.76           8.7         1.3           7.70         1.3           8.15         0.5           6.8         1           7.71         -3           -3.05         1	S         Total           D         Total           88         133           712         73           75         17           33         77           74         144           14         144           100         77           38         122           5         124           7         38           3         124           7         38           2         124           7         38           2         124           7         38           2         124           7         38           2         124           7         33           2         124           7         33           2         124           7         33           2         124           7         33           2         124           7         33           2         124           13         126           14         124	<b>B B C</b> <b>B B C</b> <b>B C</b> <b>B C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b> <b>C</b>	tine care sp - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.8 0.9 1.43 1.43 1.078 1.4 1.4 0.8 3.2 1.4	Total         Weir           144         2           121         2           171         2           173         3           141         3           53         2           533         2           383         3           668         2           333         3           67         2           711         2           233         3           237         3	Fave Sing score Std. Mean Difference pht V. Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 (0.13, 0.55] 0% 0.28 (0.05, 0.27) 5% 0.63 (0.29, 0.97) 5% 0.63 (0.29, 0.97) 5% 0.63 (0.29, 0.97) 5% 0.32 (0.44, 0.63) 7% 0.63 (0.32, 0.92] 3% 0.17 (0.01, 0.32] 7% 0.63 (0.32, 0.93] 5% 0.63 (0.32, 0.93] 5% 0.64 (0.46, 0.63) 1.2% 0.69 (0.51, 0.687) 2% 0.64 (0.65, 1.029) 5% 0.64 (0.51, 0.687) 2% 0.64 (0.65, 1.029) 5% 0.64 (0.55, 1.029) 5% 0.64 (0.65, 1.029) 5% 0.64 (0.65, 1.029) 5% 0.65 (0.51, 0.87) 2% 0.84 (0.65, 1.029) 5% 0.65 (0.51, 0.87) 5% 0.65 (0.55, 0.67) 5% 0.65 (0.51, 0.87) 5% 0.65 (0.51, 0.87)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E 7 7 6 7 7 7 7 6 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 k 2018 relly 2014 ver 2007 a 2022 (Tolephone vs Routine care) g 2022 (VDO personal devices vs Routine care) ng 2015 2014 (GMS vs Routine care) 2014 (GMS vs Routine care) 2014 (GMS vs Routine care) 2014 (GMS vs Routine care) 2015 (Telephone vs Routine care) 2016 (2015 (Telephone vs Routine care) 2017 (2015 (Telephone vs Routine care) 2018 (2015 (Telephone vs Routine care) 2014 (2018 (2015 (Telephone vs Routine care)) 2014 (2018 (201	BPITI           Mean         S           7.53         1.3           6.99         1.8           7.61         1.6           -5.47         1.7           7.61         1.6           -7.61         1.6           -7.7         1           -7.61         1.6           7.79         1.1           8.15         0.5           6.76         1.2           7.09         1.1           8.15         0.5           6.8         1           7.1         1           7.1         1           7.09         1.1           7.1         1           7.1         1           7.1         1           7.1         1           7.09         1.1           7.1         1           7.7         1           -3.05         1           7.05         3           7.05         1	S         D           18         13:           18         13:           17         12:           18         13:           17         12:           18         13:           17         12:           17         12:           18         13:           17         12:           17         14:           10         14:           10         14:           10         14:           10         12:           17         33:           33:         12:           12:         12:           12:         12:           13:         26:           13:         26:           14:         2:           10:         12:           11:         12:           12:         10:	<b>(B)</b> BC <b>Rou</b> <b>Mean</b> 9 6.29 7 6.43 9 7.41 2 -2.33 3 7.04 0 -5.97 1 6.66 4 6.65 7 -4.5 4 8.7 7 6.31 5 6.31 4 7.98 5 6.3 5 7.4 4 7.98 6 8.29 7 4.5 4 8.7 7 6.31 5 6.31 5 7.4 4 7.98 5 6.3 5 7.4 4 7.98 6 8.29 7 4.5 8 7.04 9 7.4 1 6.6 8 7.04 9 7.4 1 6.6 9 7.4 1 6.6 8 7.04 1 6.6 1 7.4 1 6.6 1 6.6 1 6.6 1 7.4 1 6.6 1 6.6 1 6.6 1 6.7 1 6.4 8 7.04 1 6.6 1 6.6 1 7.4 1 6.6 1 6.6 1 7.4 1 6.6 1 6.6 1 7.4 1 6.6 1 7.4 1 6.6 1 7.4 1 6.6 1 7.4 1 7.4 1 6.6 1 7.4 1 7.6 1 6.6 1 7.4 1 7.6 1 6.6 1 7.4 1 7.6 1 7.6 1 7.6 1 7.7 1 7.7 1 7.6 1 7.7 1 7.7 1 7.7 1 7.6 1 7.7 1	tine care SD - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.8 0.9 1.43 1.43 1.078 1.4 1.4 0.8 3.2 1.4 3.1	Total         Weir           144         2           121         2           171         2           90         2           141         3           141         3           253         2           383         3           68         2           333         3           67         2           71         2           233         3           271         2           233         3           237         3           152         2	Fave Std. Mean Difference ht. V. Random, 95% CI 9% 0.76 (0.52, 1.00) Not estimable 6% -0.24 (-0.55, 0.10) 1% 0.34 (0.13, 0.55) 0% 0.28 (0.05, 0.52) 5% 0.63 (0.29, 0.97) 5% 0.84 (0.49, 1.18) 3% 0.51 (0.37, 0.66) 4% 0.00 (-0.14, 0.14) 7% 0.62 (0.32, 0.92) 3% 0.17 (0.01, 0.32) 3% 0.17 (0.01, 0.32) 3% 0.48 (0.14, 0.81) 5% 0.84 (0.14, 0.81) 5% 0.84 (0.51, 0.67) 6% 0.63 (0.52, 0.93) 5% 0.84 (0.15, 0.67) 6% 0.63 (0.52, 0.93) 5% 0.48 (0.14, 0.81) 5% 0.84 (0.51, 0.67) 2% 0.84 (0.51, 0.67) 2% 0.84 (0.51, 0.67) 2% 0.84 (0.51, 0.67) 2% 0.71 (-0.88, 0.42) 5% 0.71 (-0.88, 0.42)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E 7 2 0 7 7 7 0 7 7 7 7 0 0 7 0 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( year) dy or Subgroup k 2018 rely 2014 vman 2014 zer 2007 n 2021 n 2019 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) 2014 (SMS vs Routine care) 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 2016 4 (SMS vs Routine care) 2015 4 (SMS vs Routine care) 2016 4 (SMS vs Routine care) 2017 4 (SMS vs Routine care) 2018 4 (SMS vs Routine care) 2018 4 (SMS vs Routine care) 2019 5 (SMS vs Routine care) 2019 5 (SMS vs Routine care) 2010 5 (SMS vs Routine care) 2010 5 (SMS vs Routine care) 2011 5 (SMS vs Routine care) 2013 5 (SMS vs Routine care) 2014 5 (SMS vs Routine care) 2014 5 (SMS vs Routine care) 2015 7 (SMS vs Routine care) 2016 7 (SMS vs Routine care) 2017 7 (SMS vs Routine care) 2018 7 (SMS vs Routine care) 2019 7 (SMS vs Routine care) 2019 7 (SMS vs Routine care) 2019 7 (SMS vs Routine care) 2010 7 (SMS vs Routine care)	BPIT           Mean         S           7.53         1.3           6.99         1.8           8.01         -2.58           -7.61         1.6           -5.47         1.7           7.61         1.6           7.73         1           -7.61         1.7           8.7         6.76           8.7         1.3           7.70         1.3           8.15         0.5           6.8         1           7.71         -3           -3.05         1	S         D         Tota           D         Tota         3         7           S         7         12:         7         3           S         7         12:         7         3           S         7         13:         3         7           S         17:         14         14:         14:           4         10:         4         10:         3           S         12:         5         12:         7         3:           3         12:         12:         7         3:         3:         12:           1         42:         12:         7         3:         2:         13:         14:         14:         14:         14:         14:         14:         14:         14:         14:         12:         12:         12:         1	<b>(B) BC</b> <b>Rou</b> <b>1 Mean</b> 9 6.29 7 6.43 9 7.41 2 -2.33 3 7.04 0 -5.97 1 6.66 4 8.7 7 6.31 5 6.31 5 6.3 5 6.3 1 7.24 2 -4.9 9 -4.18 8 -4.18 8 -5.17 -5.17	tine care sp - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.8 0.9 1.43 1.43 1.078 1.4 1.4 0.8 3.2 1.4	Total         Wei           144         2           121         2           121         2           171         3           53         2           383         3           406         3           68         2           333         3           67         2           71         2           233         3           371         2           233         3           67         2           71         2           233         3           367         2           12         233           3237         3           152         2           14         1	Favo Sing Score Std. Mean Difference ght 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) % 0.25 (0.00, 0.50) Not estimable 0.24 (0.13, 0.55) 0.63 (0.29, 0.97) 1% 0.34 (0.13, 0.55) 0% 0.28 (0.05, 0.52) 5% 0.63 (0.29, 0.97) 5% 0.63 (0.29, 0.97) 5% 0.64 (0.49, 1.18) 3% 0.51 (0.37, 0.66) 1,04, 0.63) 7% 0.62 (0.32, 0.93) 3% 0.71 (0.01, 0.52) 5% 0.84 (0.64, 0.14) 1,2% 0.69 (0.51, 0.67) 2% 0.84 (0.64, 0.14) 2% 0.84 (0.65, 1.02) 9% 0.17 (-0.88, 0.42) 3% 0.60 (0.15, 0.42) 3% 0.61 (0.15, 0.42)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E 7 2 0 7 7 7 0 7 7 7 7 0 0 7 0 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( year) dy or Subgroup k 2018 relly 2014 mman 2014 are 2007 n 2021 n 2019 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2022 (VDO personal devices vs Routine care) n 2014 (SMS vs Routine care) n 2014 2014 (SMS vs Routine care) n 2012 2015 (Telephone vs Routine care) 2016 2016 2017 2015 (Telephone vs Routine care) 2016 2018 2018 2015 (Telephone vs Routine care) 2016 2016 2017 2015 (Telephone vs Routine care) 2016 2017 2017 (VDO personal devices vs Routine care) Hee 2017 (VDO personal devices vs Routine care) 2015	BPITI           Mean         S           7.53         1.3           6.99         1.2           8.01         -           -2.58         1.3           6.99         1.2           5.47         1.7           -3.6         1           -3.6         1           -3.6         1           -3.05         1.3           -3.05         1           -3.6         1	Image: Second state         Image: Second state           Image: Second state         Image: Second state <td>B)         BCC           Rou         Rou           Image: Comparison of the state of the state</td> <td>tine care sp - 1.83 2.54 0 0.74 1.78 1.78 1.11 1.18 0.9 1.43 1.078 1.43 1.078 1.43 1.078 1.4 1.4 0.8 3.2 1.4 1.6 1.96 1.96 1.8</td> <td>Total         Weir           144         2           121         2           171         90           173         3           141         3           53         2           383         3           406         3           68         2           333         3           67         2           233         3           2371         3           2371         3           152         2           14         1           383         38</td> <td>Fave Sing score Std. Mean Difference pht V. Random, 95% CI (V. Random, 95% CI (V.</td> <td>Std. Mean Difference IV, Random, 95% CI</td> <td>Risk of Bia A B ⊂ D E 2 7 € 2 7 7 € 2 7 7 € 2 7 7 € 2 7 7 7 € 2 8 7 7 € 2 7 7 7 6 7 7 7 € 2 7 7 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7</td>	B)         BCC           Rou         Rou           Image: Comparison of the state	tine care sp - 1.83 2.54 0 0.74 1.78 1.78 1.11 1.18 0.9 1.43 1.078 1.43 1.078 1.43 1.078 1.4 1.4 0.8 3.2 1.4 1.6 1.96 1.96 1.8	Total         Weir           144         2           121         2           171         90           173         3           141         3           53         2           383         3           406         3           68         2           333         3           67         2           233         3           2371         3           2371         3           152         2           14         1           383         38	Fave Sing score Std. Mean Difference pht V. Random, 95% CI (V.	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B ⊂ D E 2 7 € 2 7 7 € 2 7 7 € 2 7 7 € 2 7 7 7 € 2 8 7 7 € 2 7 7 7 6 7 7 7 € 2 7 7 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 zer 2007 an 2021 g 2022 (VDO personal devices vs Routine care) g 2015 g 2021 (Coloponer vs Routine care) g 2016 g 2020 (VOD opersonal devices vs Routine care) g 2016 z 2014 (SMS vs Routine care) z 2015 (Telephone vs Routine care) z 2015 z 2014 z 2015 (Telephone vs Routine care) z 2015 Hee 2017 (VDO hospital vs Routine care) z 2015 Hee 2017 (VDO personal devices vs Routine care) z 2015 Hee 2017 (VDO personal devices vs Routine care) z 2015 Koutine care) z 2015 Hee 2017 (VDO personal devices vs Routine care) Hee 2017 (VDO personal	BPITI           Mean         S           7.53         1.3           6.99         1.8           7.61         1.6           7.73         1           7.74         1.7           7.75         1.3           7.76         1.6           7.71         1           7.73         1           7.74         1.7           7.75         1.3           7.70         1.1           7.70         1.1           7.70         1.1           7.70         1.1           7.70         1.1           7.70         1.1           7.70         1.1           7.70         1.1           7.70         1.1           7.70         1.1           7.71         1           7.71         1           7.71         1           7.71         1           7.71         1           7.71         1           7.71         1           7.71         1           7.71         1           7.71         1           7.71         1 </td <td>Is         Image: Constraint of the second seco</td> <td>B         B         C           R0         I         Mean           I         Mean         Image: Comparison of the c</td> <td>tine care SD - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.1 1.4 0.9 1.43 1.43 1.43 1.43 1.43 1.44 1.4 0.8 3.2 1.4 1.4 1.4 1.96 1.96 1.8 5.93</td> <td>Total         Wein           144         2           121         2           171         3           173         3           141         3           53         2           383         3           406         3           68         2           333         3           67         2           71         2           233         3           152         2           14         1           383         3           152         2           14         1           383         3           152         2           14         1           14         1           383         3           135         2</td> <td>Fave Sing score Std. Mean Difference IV. Random, 95% CI 0,000,000,000,000,000,000,000,000,000,</td> <td>Std. Mean Difference IV, Random, 95% CI</td> <td>Risk of Bia A B ⊂ D E 2 7 € 2 7 7 € 2 7 7 € 2 7 7 € 2 7 7 7 € 2 8 7 7 € 2 7 7 7 6 7 7 7 € 2 7 7 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7</td>	Is         Image: Constraint of the second seco	B         B         C           R0         I         Mean           I         Mean         Image: Comparison of the c	tine care SD - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.1 1.4 0.9 1.43 1.43 1.43 1.43 1.43 1.44 1.4 0.8 3.2 1.4 1.4 1.4 1.96 1.96 1.8 5.93	Total         Wein           144         2           121         2           171         3           173         3           141         3           53         2           383         3           406         3           68         2           333         3           67         2           71         2           233         3           152         2           14         1           383         3           152         2           14         1           383         3           152         2           14         1           14         1           383         3           135         2	Fave Sing score Std. Mean Difference IV. Random, 95% CI 0,000,000,000,000,000,000,000,000,000,	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B ⊂ D E 2 7 € 2 7 7 € 2 7 7 € 2 7 7 € 2 7 7 7 € 2 8 7 7 € 2 7 7 7 6 7 7 7 € 2 7 7 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( t overall effect: Z = 7.12 (P < 0.00001) dv or Subgroup k 2018 rely 2014 vman 2014 zer 2007 n 2021 n 2019 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) n 2014 (SMS vs Routine care) n 2014 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 (Telephone vs Routine care) 2017 (VDO personal devices vs Routine care) 1017 (VDO personal devices vs Routine care) 2015 (Zelephone vs Routine care) 2014 (SMS vs Routine care) 2015 (Telephone vs Routine care) 2014 (SMS vs Routine care) 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 (SMS vs Routine care) 2017 (VDO personal devices vs Routine care) 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 (SMS vs Routine care) 2017 (VDO personal devices vs Routine care) 2018 (SMS vs Routine care) 2014 (SMS vs Routine care) 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 (SMS vs Routine care) 2017 (VDO personal devices vs Routine care) 2018 (SMS vs Routine care) 2019 (SMS vs Routine care) 2019 (SMS vs Routine care) 2010 (SMS vs Routine care) 2010 (SMS vs Routine care) 2011 (SMS vs Routine care) 2011 (SMS vs Routine care) 2012 (SMS vs Routine care) 2013 (SMS vs Routine care) 2014 (SMS vs Routine care) 2014 (SMS vs Routine care) 2015 (SMS vs Routine care) 2015 (SMS vs Routine care) 2016 (SMS vs Routine care) 2017 (SMS vs Routine care) 2018 (SMS vs Routine care) 2019 (SMS vs Routine care) 2019 (SMS vs Routine care) 2010 (SMS v	$\begin{array}{c c} \mathbf{B} \\ $	Signed         Signed           D         Tota           P         Tota           Signed		tine card sp 1.83 2.54 0 0.74 1.78 1.1 1.1 1.8 0.9 1.43 1.43 1.43 1.43 1.43 1.43 1.44 1.44 1.44 1.44 1.44 1.44 1.44 1.44 1.44 1.44 1.44 1.44 1.45 1.44 1.45 1.44 1.45 1.44 1.45 1.96 1.86 1.96 1.85 1.95 1.85 1.95 1.85 1.95 1.85 1.95	Fotal         Weii           144         2           121         2           171         90           90         2           173         3           141         3           53         2           53         2           383         3           668         2           67         2           71         2           233         3           67         2           71         2           233         3           152         2           154         1           152         2           14         1           3135         2           135         2           252         3	Fave Sing score Std. Mean Difference by V. Random, 95% CI (V.	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B ⊂ D E ? ? • • ? ? ? • ? • ? ? ? • • • ? ? • • • •
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 zer 2007 an 2021 g 2022 (CDO personal devices vs Routine care) g 2022 (CDO personal devices vs Routine care) g 2016 vani 2020 2016 (MS vs Routine care) a 2014 (Telephone vs Routine care) a 2014 (Telephone vs Routine care) a 2014 (SMS vs Routine care) a 2012 (SMS vs Routine care) a 2014 2015 (relephone vs Routine care) a 2012 2015 (Glephone vs Routine care) 2015 (relephone vs Routine care) 2016 wani 2020 2015 (Telephone vs Routine care) 2016 Hee 2017 (VDO hospital vs Routine care) 2016 Hee 2017 (VDO hospital vs Routine care) 2016 k 2015 Hee 2017 (VDO personal devices vs Routine care) 2016 k 2016 k 2016	BPITI           Mean         S           7.53         1.3           6.99         1.8           7.61         1.6           7.61         1.6           7.61         1.6           7.70         1.7           7.70         1.7           7.70         1.7           7.70         1.7           8.7         6.76           7.70         1.3           8.15         0.5           6.8         1           7.70         1.1           7.70         1.2           7.70         1.3           8.15         0.5           6.8         1           7.70         1.1           7.70         1.3           7.70         1.3           7.70         1.3           7.70         1.1           -3.05         1           -4.37         1.6           -3.05         1           -3.05         1           -3.05         1           -3.05         1           -3.07         1           -3.03         1           8.67	Signed         Signed           D         Tota           P         Tota           Signed	(B) BCC Round (B) BCC Round (C) Constant (C) Constant	tine care SD - 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.1 1.1 1.4 0.9 1.43 1.43 1.43 1.43 1.43 1.44 1.4 0.8 3.2 1.4 1.4 1.4 1.96 1.96 1.8 5.93	Fotal         Weii           144         2           121         2           171         90           90         2           173         3           141         3           53         2           53         2           383         3           668         2           67         2           71         2           233         3           67         2           71         2           233         3           152         2           154         1           152         2           14         1           3135         2           135         2           252         3	Fave Sing score Std. Mean Difference IV. Random, 95% CI 0,000,000,000,000,000,000,000,000,000,	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B ⊂ D E         Y 2 O 7          Y 2 O 7          Y 2 O 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 zer 2007 an 2021 g 2022 (Clelephone vs Routine care) g 2022 (Clo personal devices vs Routine care) g 2022 (Clo personal devices vs Routine care) g 2020 (Sub or skoutine care) a 2014 (Flelephone vs Routine care) a 2015 (SiMS vs Routine care) a 2015 (SiMS vs Routine care) a 2015 (SiMS vs Routine care) 2016 wani 2020 2015 (SiMS vs Routine care) 2015 (SiMS vs Routine care) 2016 wani 2020 2017 (VDD personal devices vs Routine care) 2016 We 2017 (VDD hospital vs Routine care) 2016 We 2017 (VDD personal devices vs Routine care) 2015 k 2016 k 2015 k 2015 k 2015 k 2015	BPITI           Mean         S           7.53         1.3           7.69         1.8           -2.58         1           7.61         1.6           7.61         1.6           7.61         1.6           7.73         1           7.61         1.6           7.71         1           7.73         1           7.74         1.7           7.79         1.1           7.70         1.1           7.70         1.7           1         7.70           7.70         1.7           1         7.70           7.71         1           7.70         1.1           7.70         1.1           7.70         1.3           7.70         1.1           7.70         1.1           -3.5         1           -4.37         1.6           -3.03         1           -3.67         0.7           -3.03         1           -3.67         0.7	Image: Second	(B) BC (B) BC (B) BC (B) BC (B) BC (B) BC (B) BC (C) (C) (C) (C) (C) (C) (C) (C	tine cars SD 1.83 2.54 0 0.74 1.78 1.11 1.8 0.9 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.44 1.4 0.8 3.2 1.4 1.4 1.4 0.5 1.45 1.96 1.96 1.88 5.93 1.48 1.48	Total         Wei           144         2           121         2           171         90           90         2           173         3           141         3           53         2           383         3           68         2           333         3           67         2           231         3           152         2           14         1           383         3           152         2           14         1           383         3           152         2           14         1           383         3           135         2           252         3           3135         2           252         3           95         2           48         66	Fave Sing score Std. Mean Difference ht V. Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) 1% 0.34 (0.15, 0.51) 0.34 (0.15, 0.52) 5% 0.84 (0.49, 1.18) 3% 0.51 (0.37, 0.66] 4% 0.00 (-0.14, 0.14) 7% 0.63 (0.32, 0.92) 3% 0.41 (0.51, 0.63) 7% 0.63 (0.32, 0.93) 5% 0.48 (0.49, 0.18) 2% 0.69 (0.51, 0.47) 4% 0.45 (-0.19), 1.10) 3% 0.51 (0.37, 0.66] 9% 0.00 (-0.24, 0.24) 9% 0.02 (0.24, 0.44) 3% 0.65 (0.15, 1.46) 4% 0.45 (-0.19), 1.10) 3% 0.62 (0.44, 0.80) 5% 0.51 (0.37, 0.66] 9% 0.00 (-0.24, 0.24) 2% 0.62 (0.44, 0.80) 5% 0.51 (0.21, 0.66] Not estimable 4% 0.76 (0.11, 1.11)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E C D E C D C C C C C C C C C C C C C C C C C C
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( troroverall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 roll 2014 trans 2014 trans 2014 trans 2014 trans 2014 2022 (Telephone vs Routine care) 2 2022 (Telephone vs Routine care) 2 2022 (VDO personal devices vs Routine care) 2 2014 (SMS vs Routine care) 2 2015 (Telephone vs Routine care) 2 2 2 2 (VDO personal devices vs Routine care) 2 2 105 1 (VDO personal devices vs Routine care) 2 2 15 4 ke 2 0 17 (VDO personal devices vs Routine care) 2 2 15 4 ke 2 0 17 (VDO personal devices vs Routine care) 2 2 15 4 ke 2 0 13 2 2 10 16 4 ka h 2 0 13 2 2 10 6	$\begin{array}{c} \text{BPIT}\\ \text{Mean} & \text{S}\\ \hline \\ \text{Mean} & \text{S}\\ \hline \\ \text{7.53} & 1.3\\ 6.99 & 1.8\\ 8.01\\ -2.58 & 1\\ 7.61 & 1.6\\ -5.47 & 1.7\\ 7.3 & 1\\ 7.7 & 1\\ -7.7 & 1\\ -3.6 & 1\\ 7.7 & 1\\ -3.6 & 1\\ 7.1 & 1\\ 7.7 & 1\\ -3.7 & 2.2\\ -7 & 1.2\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -7 & 1\\ -8$	D         Total           D         Total           B         13:3           13:17         12:3           13:17         12:3           13:17         12:3           14:1         10:0           15:5         17:7           15:5         17:7           16:1         14:1           17         32:3           16:2         12:1           17         33:2           10:1         7:3           26:3         12:1           10:3         22:1           10:3         22:1           11:3         33:2           13:3         23:1           14:3         19:1           15:3         22:1           10:3         23:1           11:3         33:1           12:4         14:4           14:5         12:1           15:3         22:1           10:3         23:1           11:3         31:1           12:4         14:1           14:5         12:1           15:1         13:1           16:1         13:1           17:1	(B)         BC           Row         Row           I         Mean           0         6.29           7         6.43           2         -2.33           3         7.04           2         -2.33           3         7.04           2         -2.33           3         7.04           4         6.66           5         6.31           5         6.33           5         6.33           5         6.33           5         6.33           5         6.33           5         6.33           5         6.33           5         6.33           5         6.33           5         6.33           6.52         5           0         -5.17           7         7           5         5           5         -5           10         8           10         8           10         8           10         8           10         8           10         8 <t< td=""><td>tine carcs 1.83 2.54 0.74 1.7 1.78 1.1 1.1 1.4 1.43 1.078 1.43 1.078 1.43 1.078 1.4 1.4 1.4 1.9 1.9 1.8 5.93 1.9 1.8 5.93 1.9 1.8 1.9 1.8 5.93 1.9 1.48 1.9 1.9 1.8 5.93 1.9 1.48 1.9 1.8 5.93 1.9 1.48 1.8 5.93 1.9 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.8 5.93 1.9 1.48 1.48 5.93 1.9 1.48 1.48 5.93 1.9 1.48 5.93 1.9 5.93 1.9 5.93 1.9 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 5.93 1.98 5.93</td><td>Total         Wein           144         2           121         2           171         90           90         2           173         3           141         3           53         2           383         3           668         2           333         3           67         2           71         2           233         3           237         3           152         2           144         1           383         3           67         2           71         2           233         3           152         2           14         1           383         3           95         2           48         6           650         2</td><td>Favo Sing Score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 0.34 (0.13, 0.55) 0% 0.28 (0.00, 0.52) 1% 0.34 (0.13, 0.55) 0% 0.28 (0.05, 0.52) 5% 0.84 (0.49, 1.18) 3% 0.51 (0.37, 0.66) 4% 0.00 (-0.14, 0.14) 7% 0.62 (0.32, 0.92) 3% 0.17 (0.01, 0.32) 5% 0.84 (0.46, 1.02) 7% 0.37 (0.07, 0.67) 6% 0.63 (0.52, 0.93) 5% 0.48 (0.14, 0.81) 2% 0.84 (0.65, 1.02) 9% 0.17 (-0.80, 0.42) 3% 0.51 (0.37, 0.66) 4% 0.46 (-0.15, 1.06] 5% 0.84 (0.65, 1.02) 9% 0.17 (-0.88, 0.42) 3% 0.51 (0.37, 0.66) 3% 0.51 (0.37, 0.66) 9% 0.00 (-0.24, 0.24) 2% 0.57 (0.24, 1.13) 2% 0.76 (0.41, 1.13) 2% 0.76 (0.41, 1.13)</td><td>Std. Mean Difference IV, Random, 95% CI</td><td>Risk of Bia A B C D E 7 0 0 7 7 0 7 0 7 7 0 0 7 7 0</td></t<>	tine carcs 1.83 2.54 0.74 1.7 1.78 1.1 1.1 1.4 1.43 1.078 1.43 1.078 1.43 1.078 1.4 1.4 1.4 1.9 1.9 1.8 5.93 1.9 1.8 5.93 1.9 1.8 1.9 1.8 5.93 1.9 1.48 1.9 1.9 1.8 5.93 1.9 1.48 1.9 1.8 5.93 1.9 1.48 1.8 5.93 1.9 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.8 5.93 1.9 1.48 1.48 5.93 1.9 1.48 1.48 5.93 1.9 1.48 5.93 1.9 5.93 1.9 5.93 1.9 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 1.98 5.93 5.93 1.98 5.93	Total         Wein           144         2           121         2           171         90           90         2           173         3           141         3           53         2           383         3           668         2           333         3           67         2           71         2           233         3           237         3           152         2           144         1           383         3           67         2           71         2           233         3           152         2           14         1           383         3           95         2           48         6           650         2	Favo Sing Score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 0.34 (0.13, 0.55) 0% 0.28 (0.00, 0.52) 1% 0.34 (0.13, 0.55) 0% 0.28 (0.05, 0.52) 5% 0.84 (0.49, 1.18) 3% 0.51 (0.37, 0.66) 4% 0.00 (-0.14, 0.14) 7% 0.62 (0.32, 0.92) 3% 0.17 (0.01, 0.32) 5% 0.84 (0.46, 1.02) 7% 0.37 (0.07, 0.67) 6% 0.63 (0.52, 0.93) 5% 0.48 (0.14, 0.81) 2% 0.84 (0.65, 1.02) 9% 0.17 (-0.80, 0.42) 3% 0.51 (0.37, 0.66) 4% 0.46 (-0.15, 1.06] 5% 0.84 (0.65, 1.02) 9% 0.17 (-0.88, 0.42) 3% 0.51 (0.37, 0.66) 3% 0.51 (0.37, 0.66) 9% 0.00 (-0.24, 0.24) 2% 0.57 (0.24, 1.13) 2% 0.76 (0.41, 1.13) 2% 0.76 (0.41, 1.13)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E 7 0 0 7 7 0 7 0 7 7 0 0 7 7 0
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 40 tr for overall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 relly 2014 wman 2014 ere 2007 n 2021 g 2022 (Tolephone vs Routine care) g 2022 (Tolephone vs Routine care) g 2022 (Tolephone vs Routine care) g 2020 (VD opersonal devices vs Routine care) g 2016 vani 2020 12014 (Telephone vs Routine care) 12022 (SMS vs Routine care) 12015 (SMS vs Routine care) 12015 (SMS vs Routine care) 12016 2015 (SMS vs Routine care) 12016 2015 (SMS vs Routine care) 12017 (VDD hospital vs Routine care) 12018 42015 the 2017 (VDD hospital vs Routine care) 12018 kash 2018 kash 2013 2016	$\begin{array}{c} \textbf{BPITI}\\ \hline \textbf{Mean} & \textbf{S}\\ \hline \textbf{S}\\ \textbf{S}\\$	DOUDI);   D Tota D Tota 133 77 125 14 14 14 10 10 17 33 12 12 12 12 12 12 12 12 12 12	Rou           I         Mean           0         0.29           7         6.43           9         7.643           2         -2.33           3         7.04           2         -2.33           3         7.04           2         -3.33           7         6.51           6         6.66           6         6.65           6         6.35           5         6.33           5         6.33           5         6.33           5         6.33           5         6.33           5         6.35           6         -5.17           7         -5.17           7         -5.17           7         -5.17           7         -5.17           7         -5.17           7         -5.17           7         -5.17           7         -5.17           7         -5.2           6.63         -5.2           6.5         -4.20           8         -5.2           2         2	tine cards 1.83 2.54 0 0.74 1.7 1.78 1.1 1.8 0.9 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.96 1.88 1.9 1.96 1.84 1.95 1.84 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85 1.84 1.85	Total         Wein           144         2           141         2           171         90           90         2           173         3           141         3           53         2           383         3           406         3           668         2           333         3           67         2           71         2           237         3           152         2           141         1           383         3           152         2           711         2           237         3           1355         2           2437         3           1355         2           252         3           3135         2           252         3           48         66           2         50           486         2           500         2           500         2	Fave Sing score Std. Mean Difference ht V. Random, 95% CI 0, 0.25 [0.00, 0.50] 0, 0.25 [0.00, 0.50] 0, 0.25 [0.00, 0.50] 0, 0.25 [0.00, 0.50] 0, 0.24 [0.05, 0.07] 1% 0.34 [0.13, 0.55] 0, 0.24 [0.05, 0.52] 1% 0.63 [0.29, 0.97] 5% 0.84 [0.49, 1.18] 3% 0.51 [0.37, 0.66] 4% 0.00 [-0.14, 0.14] 7% 0.63 [0.32, 0.93] 3% 0.45 [0.13, 0.61] 2% 0.84 [0.49, 0.18] 2% 0.84 [0.40, 0.18] 2% 0.84 [0.40, 0.18] 2% 0.84 [0.40, 0.18] 2% 0.84 [0.40, 0.42] 3% 0.45 [-0.19, 1.10] 3% 0.51 [0.37, 0.66] 4% 0.05 [-0.19, 1.10] 3% 0.51 [0.37, 0.66] 5% 0.50 [0.51, 0.46] 5% 0.50 [0.51, 0.46] 5% 0.50 [0.51, 0.46] 5% 0.51 [0.13, 0.66] 5% 0.51 [0.13, 0.66] 5% 0.51 [0.13, 0.66] 5% 0.51 [0.14, 0.41] 2% 0.62 [0.44, 0.80] 5% 0.51 [0.12, 0.66] 5% 0.51 [0.12, 0.56] 5% 0.51 [0.12, 0.56] 5% 0.51 [0.12, 0.56] 5% 0.51 [0.12, 0.56] 5% 0.51 [0.12, 0.56] 5	Std. Mean Difference IV, Random, 95% CI	Risk of Bia A B C D E Q
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( troroverall effect: Z = 7.12 (P < 0.00001) dy or Subgroup k 2018 rely 2014 ren 2014 rer 2007 ren 2021 2022 (Telephone vs Routine care) 2 2022 (VDO personal devices vs Routine care) 2 2025 (SløS vs Routine care) 2 2014 GMS vs Routine care) 2 2015 (Telephone vs Routine care) 2 2 015 (Telephone vs Routine care) 2 015 (VDO personal devices vs Routine care) 2 016 k 2 015 k 2 016 k 2 016 k 2 016 k 2 016 k 2 016 k 2 017 x 2	$\begin{array}{c} \textbf{BPITI}\\ \hline \textbf{Mean} & \textbf{S}\\ \hline \textbf{S}\\ \textbf{S}\\$	D         Total           D         Total           Total         13/1           Total         13/1           Total         13/1           Total         13/1           Total         13/1           Total         13/1           Total         14/1           Total         14/1           Total         14/1           Total         12/2           Total         14/2           Total         12/2           Total         12/2           Total         12/2           Total         13/2           Total         13/2           Total         13/2           Total         14/2           Total         14/2           Total         14/2           Total         14/2           Total         14/2           Total         14/2	(B)         BC           Row         Row           I         Mean           0         6.29           7         6.43           2         -2.33           3         7.04           2         -2.33           3         7.04           4         6.69           7         -4.51           6         6.31           7         6.63           1         7.24           9         -4.18           8         16.52           0         -5.17           7         -5.5           0         -5.17           7         -5.52           0         -5.17           7         -5.52           0         -5.17           7         -5.52           0         -5.17           7         -5.52           0         -5.17           7         -5.52           0         -5.17           7         -5.52           0         -6.42           8         5           5         -6.63           5         -6.54<	tine carcs 1.83 2.54 0.74 1.7 1.78 1.1 1.1 1.4 1.43 1.078 1.43 1.078 1.43 1.078 1.4 1.4 1.4 1.9 1.9 1.8 5.93 1.9 1.8 5.93 1.9 1.8 1.9 1.8 5.93 1.9 1.43 1.9 1.8 5.93 1.9 1.48 1.9 1.9 1.8 5.93 1.9 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.8 5.93 1.9 1.48 1.48 1.48 1.9 1.8 5.93 1.9 1.48 1.48 1.48 1.8 5.93 1.9 1.48 1.48 5.93 1.9 1.48 1.48 5.93 1.9 1.48 5.93 1.9 5.93 1.9 5.93 1.9 5.93 1.98 5.93 5.9	Total         Wein           144         2           121         2           171         90           2         171           3         3           53         2           383         3           406         3           68         2           71         2           233         3           667         2           71         2           233         3           267         2           152         2           144         1           183         3           233         3           667         2           233         3           152         2           14         1           135         2           90         2           80         2           80         2           80         2           80         2           80         2           80         2           80         2           80         2           80         2	Favo Sing Score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 0.34 (0.13, 0.55) 0% 0.28 (0.00, 0.52) 1% 0.34 (0.13, 0.55) 0% 0.28 (0.05, 0.52) 5% 0.84 (0.49, 1.18) 3% 0.51 (0.37, 0.66) 4% 0.00 (-0.14, 0.14) 7% 0.62 (0.32, 0.92) 3% 0.17 (0.01, 0.32) 5% 0.84 (0.46, 1.02) 7% 0.37 (0.07, 0.67) 6% 0.63 (0.52, 0.93) 5% 0.48 (0.14, 0.81) 2% 0.84 (0.65, 1.02) 9% 0.17 (-0.80, 0.42) 3% 0.51 (0.37, 0.66) 4% 0.46 (-0.15, 1.06] 5% 0.84 (0.65, 1.02) 9% 0.17 (-0.88, 0.42) 3% 0.51 (0.37, 0.66) 3% 0.51 (0.37, 0.66) 9% 0.00 (-0.24, 0.24) 2% 0.57 (0.24, 1.13) 2% 0.76 (0.41, 1.13) 2% 0.76 (0.41, 1.13)	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? @ ? ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ? ?         ? @ ? @ ? ? ?         ? @ ? @ ? ? ?         ? @ ? ? ? ?         ? @ ? ? ? ? ?         ? @ ? ? ? ?         ? @ ? ? ? ? ? ? ? ? ? ? ? ?         ? @ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dv or Subgroup k 2018 rely 2014 wman 2014 zer 2007 a 2021 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2023 (SM vs Routine care) 2014 (SM vs Routine care) 2015 (Telephone vs Routine care) 2016 te 2017 (VDO hospital vs Routine care) 12018 a 2018 a 2018 a 2018 a 2018 a 2017 nowicz 2022 der Zander 2021 divijzen 2020	$\begin{array}{c} \mathbf{BPIT}\\ \mathbf{Mean} & \mathbf{S}\\ 7, 53 & 1, 3\\ 7, 53 & 1, 3\\ 6, 99 & 1, 8\\ 8, 01\\ -2, 58 & 1, 7, 71 & 1\\ -3, 61 & 1, 6\\ 7, 71 & 1\\ -3, 61 & 1, 6\\ 7, 71 & 1\\ -3, 61 & 1, 7, 71 & 1\\ 7, 71 & 1\\ 7, 71 & 1\\ 7, 71 & 1\\ 7, 71 & 1\\ 7, 71 & 1\\ 7, 71 & 1\\ 7, 71 & 1\\ 7, 71 & 1\\ 71 & 1\\ 71 & 1\\ 71 & 1\\ 71 & 1\\ 71 & 71 & 1\\ 71 & 71 & 1\\ 71 & 71 & 1\\ 71 & 71 & 71\\ 71$	Sis         Total           18         13:3           18         13:3           17         12:5           17         15:5           17         13:7           17         15:5           17         14           14         10           11         10:0           12         12:1           13         23:1           14         14:1           13         23:2           14:1         10:1           13:1         21:1           14:1         10:1           13:1         21:1           14:1         10:1           14:1         10:1           14:1         10:1           17:3         26:1           16:1         32:1           17:3         26:1           17:3         26:1           10:1         31:3           14:1         31:3           14:1         31:3           15:2         16:1           16:1         12:1           17:3         26:1           16:1         31:1           17:3         32:1     <	B         B         C           Rou         Rou         Rou           I         Mean         0         6.29           7         6.43         7.41         2           2         -3.37         7.04         0         -5.97           2         -3.33         6.33         7.04         0         -5.97           4         6.6         7         6.31         7.45         5         6.31         1         7.24         4         7.98         6         3         1         7.24         4         7.98         6         3         1         7.45         5         6.31         1         7.24         4         9.9         -4.16         2         2.33         6.33         6.33         6.33         6.33         6.33         6.33         6.33         6.33         6.33         6.33         6.33         6.34         7         5         5.17         7         -5.57         7         -5.55         5         -5.17         7         -5         5         5         -6.421         1         8         6.67         7         -5         5         -5         5         -5         5         -5         5	tine carc SD - 	Total         Wein           144         2           147         2           171         90           2         173           3         3           406         3           68         2           333         3           67         2           711         2           233         3           67         2           71         2           233         3           67         2           71         2           233         3           67         2           71         2           233         3           67         2           71         2           233         3           67         2           14         1           135         2           80         2           80         2           80         2           80         2           80         2           81         2           200         274           81         2	Favo Sing Score Std. Mean Difference ht V. Random, 95% CI 9% 0.76 [0.52, 1.00] Not estimable 6% 0.25 [0.00, 0.50] Not estimable 1.025 [0.00, 0.50] 0.25 [0.00, 0.50] 1.03 (0.24, 0.53, 0.55] 0.34 [0.13, 0.55] 0.34 [0.13, 0.55] 0.34 [0.49, 1.13] 1.3% 0.51 [0.37, 0.66] 4.00 (0.14, 0.14] 7% 0.62 [0.24, 0.63] 1.5% 0.34 [0.14, 0.81] 2.6% 0.63 [0.52, 0.93] 1.5% 0.48 [0.14, 0.81] 2.8% 0.51 [0.57, 0.66] 0.48 [0.51, 0.87] 2.8% 0.48 [0.51, 0.87] 2.8% 0.51 [0.57, 0.66] 3.8% 0.51 [0.57, 0.64] 3.8% 0.51 [0.57, 0.66] 3.8% 0.51 [0.27, 0.66] 3.8% 0.51 [0.21, 0.66] 3.8% 0.51 [0.21, 0.66] 3.8% 0.51 [0.21, 0.66] 3.8% 0.51 [0.21, 0.66] 3.8% 0.53 [0.21, 0.66] 3	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         7 2 0 7 7         7 7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( stroroverall effect: Z = 7.12 (P < 0.00001) <b>dy or Subgroup</b> t: 2018 trelly 2014 winar 2014 zer 2007 n 2019 g 2022 (tolephone vs Routine care) g 2022 (tolephone vs Routine care) g 2022 (tolephone vs Routine care) g 2022 (tolephone vs Routine care) n 2014 (SMS vs Routine care) n 2014 (Clephone vs Routine care) n 2015 (SMS vs Routine care) n 2015 (SMS vs Routine care) n 2015 (SMS vs Routine care) 2015 (SMS vs Routine care) 2016 (Clephone vs Routine care) 2015 (SMS vs Routine care) 2015 (SMS vs Routine care) 2015 (SMS vs Routine care) 2016 2014 2018 2018 al 2018 al 2018 al 2018 al 2018 al 2018 al 2018 cara 2017 conswicz 2022 ci der Zander 2021 dhuijzen 2020 ker 2022	$\begin{array}{c} \mathbf{BPIT}\\ \hline \mathbf{Mean} & \mathbf{S}\\ 7, 53 & 1, 3\\ 6, 99 & 1, 8\\ 8, 01\\ \mathbf{-2}, 58 & 1, 7, 51 & 1, 3\\ 7, 61 & 1, 61 & 1, 61\\ 7, 61 & 1, 61 & 1, 61\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 1\\ 7, 7 & 1 & 7\\ 7, 7 & 1, 7 & 7\\ 7 & 7 & 7\\ 7 & 7 & 7\\ 7 & 7 & 7\\ 7 & 7 & 1, 1\\ 7 & 7 & 7\\ 7 & 7 & 7\\ 7 & 7 & 7\\ 7 & 7 & 1, 1\\ 7 & 7 & 7\\ 7 & 7 & $	Solution         Solution           1         1         1           1         1         1         1           1         1         1         1         1           1         1         1         1         1         1           1	(B)         BC           Rou         Rou           Mean         6.29           7         6.43           7         6.43           7         6.43           7         7.43           2         -2.33           7.41         7.45           6.31         7.44           5         6.31           6         6.33           7         -4.5           8         16.52           6         -5.17           7         -5.57           5         -5.17           7         -5.57           5         -6.57           6         -6.57           7         -5.57           7         -5.67           7         -5.70           7         -5.70           9         7           9         7           9         7           9         7	time carc SD 1.83 2.54 0 0.74 1.7 1.78 1.1 1.1 1.8 0.9 1.43 1.47 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.95 1.85 1.9 1.45 1.9 1.9 1.48 0.9 0 0 0 0 0 0 0 0 0 0 0 0 0	Total         Wein           Total         2           121         2           121         2           171         2           173         3           141         3           53         2           383         3           668         2           67         2           237         3           152         2           237         3           152         2           14         1           143         35           252         3           3135         2           2552         3           3066         2           466         2           50         2           466         2           500         2           274         2           481         2           217         3           102         2	Favo Sing score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.76 (0.52, 1.00) 9% 0.76 (0.52, 1.00) 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) 5% 0.24 [-0.55, 0.07] 1% 0.34 (0.13, 0.55] 5% 0.63 (0.23, 0.92] 5% 0.63 (0.24, 0.49, 1.18] 3% 0.51 (0.37, 0.66] 4% 0.00 (-0.14, 0.14] 7% 0.63 (0.32, 0.92] 3% 0.61 (0.32, 0.92] 3% 0.61 (0.32, 0.93] 5% 0.48 (0.49, 1.18] 2% 0.69 (0.51, 0.87] 2% 0.61 (0.15, 1.66] 9% 0.07 [-0.08, 0.42] 9% 0.07 [-0.38, 0.42] 9% 0.07 [-0.38, 0.42] 9% 0.07 [-0.38, 0.42] 9% 0.07 [-0.44, 0.80] 5% 0.53 [0.21, 0.86] 9% 0.07 [-0.24, 0.24] 103 0.71 [-0.24, 0.34] 112 0.71 [-0.24, 0.35] 0.71 [-0.24, 0.35] 0.71 [-0.24, 0.35] 0.71 [-0.24, 0.35] 103 0.71 [-0.24, 0.35] 103 0.71 [-0.24, 0.58] 103 0.71 [-0.24, 0.58] 104 0.75 [-0.29, 0.53] 105 0.05 (0.69] 105 0.05 (0.69] 105 0.05 (0.69) 105 0.05 (0.59) 105 0.05 (0.	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? ? @ ? ? ?         ? @ ? ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ?         ? @ ? @ ? ? ?         ? @ ? @ ? ? ?         ? @ ? @ ? ? ?         ? @ ? ? ? ?         ? @ ? ? ? ? ?         ? @ ? ? ? ?         ? @ ? ? ? ? ? ? ? ? ? ? ? ?         ? @ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) <b>dy or Subgroup</b> ix 2018 rely 2014 wman 2014 zer 2007 an 2021 g 2022 (Telephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2021 (SMS vs Routine care) 2014 (SMS vs Routine care) 2014 (SMS vs Routine care) 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 2017 (VDO hospital vs Routine care) 2016 Hee 2017 (VDO hospital vs Routine care) 12015 k 2016 el 2018 a 2016 el 2018 a 2016 el 2018 a 2016 el 2018 a 2016 care 2017 mowicz 2022 der Zander 2021 dhuijzen 2020 lker 2020 lker 2020 ker 2022	$\begin{array}{c} \mathbf{BPIT}\\ \mathbf{Mean} & \mathbf{S}\\ 7, 53 & 1, 3\\ 6, 99 & 1, 8\\ 8, 01\\ -2, 58 & 1, 7, 31 & 1\\ 7, 71 & 1\\ -3, 61 & 1, 6\\ 7, 71 & 1\\ 7, 7, 71 & 1\\ 7, 7, 7, 7, 7, 7 & 7\\ 7, $	Sis         Total           18         13:3           17         12:3           18         13:3           17         12:5           17         13:5           11         10:0           12         12:1           11         14:2           12         12:1           13         3:1           14         14:0           13         3:1           14         14:0           13         3:2           14         14:0           15         12:1           16:3         2:2           17         38           13         3:1           14:3         14:2           15:3         12:2           16:3         2:2           17:3         2:6           18:3         4:4           10:0         3:2           10:0         3:2           10:0         3:2           10:0         3:2           10:0         3:2           10:0         3:2           10:0         3:2           10:0         3:2 <t< td=""><td>B         B         C           Rou         Rou         Rou           I         Mean         0         6.29           7         6.43         7.41         2           2         -3.37         7.04         0         -5.97           2         -3.33         6.33         3         7.04           0         -5.97         6.31         1         7.45         5           1         7.45         5         6.33         1         7.24         9         -6.16         5         6.33         6.35         5.517         7         -5.55         5         -5.17         7         -5.55         5         -5.17         7         -5         5         -5.17         7         -5         5         -5         5         -5         -5         5         -5         -5         -5         -5         -5         -5         -5</td><td>tine carc SD 1.83 0 0.74 1.7 1.78 1.8 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4</td><td>Total         Wein           144         2           147         2           171         90           2         171           3         3           53         2           383         3           406         3           68         2           333         3           67         2           2333         3           67         2           2333         3           67         2           2333         3           67         2           2333         3           67         2           2333         3           67         2           152         2           252         3           95         2           48         2           50         2           80         2           81         2           217         3           102         2           247         3</td><td>Favo Sing Score Std. Mean Difference ht V, Random, 95% CI 9% 0.76 (0.52, 1.00) Not estimable 0.32 (0.00, 0.50) Not estimable 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.33 (0.40, 9, 1.13) 3% 0.51 (0.37, 0.66) 4% 0.00 (-0.14, 0.14) 7% 0.62 (0.32, 0.92) 3% 0.17 (0.01, 0.32) 3% 0.63 (0.32, 0.93) 5% 0.48 (0.45, 1.02) 3% 0.71 (0.70, 6.77) 6% 0.63 (0.32, 0.93) 5% 0.48 (0.45, 1.02) 3% 0.71 (0.70, 6.77) 2% 0.84 (0.65, 1.02) 3% 0.51 (0.37, 0.66) 4% 0.75 (-0.14, 0.14) 2% 0.62 (0.44, 0.81) 3% 0.51 (0.37, 0.66) 5% 0.51 (0.37, 0.66) 5% 0.53 (0.21, 0.86) Not estimable 6% 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 2% 0.51 (-0.30, 0.06) 8% 0.25 [-0.02, 0.52] 2% 0.57 (-0.39, 0.57) 3% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.51] 5% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.51] 5% 0.51 [-0.30, 0.55] 5% 0</td><td>Std. Mean Difference IV, Random, 95% CI</td><td>Risk of Bia         A B C D E         7 2 0 7 7         7 7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7</td></t<>	B         B         C           Rou         Rou         Rou           I         Mean         0         6.29           7         6.43         7.41         2           2         -3.37         7.04         0         -5.97           2         -3.33         6.33         3         7.04           0         -5.97         6.31         1         7.45         5           1         7.45         5         6.33         1         7.24         9         -6.16         5         6.33         6.35         5.517         7         -5.55         5         -5.17         7         -5.55         5         -5.17         7         -5         5         -5.17         7         -5         5         -5         5         -5         -5         5         -5         -5         -5         -5         -5         -5         -5	tine carc SD 1.83 0 0.74 1.7 1.78 1.8 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4	Total         Wein           144         2           147         2           171         90           2         171           3         3           53         2           383         3           406         3           68         2           333         3           67         2           2333         3           67         2           2333         3           67         2           2333         3           67         2           2333         3           67         2           2333         3           67         2           152         2           252         3           95         2           48         2           50         2           80         2           81         2           217         3           102         2           247         3	Favo Sing Score Std. Mean Difference ht V, Random, 95% CI 9% 0.76 (0.52, 1.00) Not estimable 0.32 (0.00, 0.50) Not estimable 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.34 (0.13, 0.55) 0.33 (0.40, 9, 1.13) 3% 0.51 (0.37, 0.66) 4% 0.00 (-0.14, 0.14) 7% 0.62 (0.32, 0.92) 3% 0.17 (0.01, 0.32) 3% 0.63 (0.32, 0.93) 5% 0.48 (0.45, 1.02) 3% 0.71 (0.70, 6.77) 6% 0.63 (0.32, 0.93) 5% 0.48 (0.45, 1.02) 3% 0.71 (0.70, 6.77) 2% 0.84 (0.65, 1.02) 3% 0.51 (0.37, 0.66) 4% 0.75 (-0.14, 0.14) 2% 0.62 (0.44, 0.81) 3% 0.51 (0.37, 0.66) 5% 0.51 (0.37, 0.66) 5% 0.53 (0.21, 0.86) Not estimable 6% 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 0.38 (0.06, 0.69) 2% 0.51 (-0.30, 0.06) 8% 0.25 [-0.02, 0.52] 2% 0.57 (-0.39, 0.57) 3% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.51] 5% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.65] 3% 0.51 [-0.30, 0.51] 5% 0.51 [-0.30, 0.55] 5% 0	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         7 2 0 7 7         7 7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 40 st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> .t. 2018 relly 2014 wman 2014 zer 2007 en 2021 ig 2022 (Telephone vs Routine care) ig 2022 (VDO personal devices vs Routine care) ig 2022 (VDO personal devices vs Routine care) n 2014 (SMS vs Routine care) n 2014 (ISMS vs Routine care) n 2014 (ISMS vs Routine care) n 2012 2015 (Clephone vs Routine care) 2016 (SMS vs Routine care) 2016 2017 (VDO hospital vs Routine care) -Hee 2017 (VDO personal devices vs Routine care) 1 2018 k 2015 +Lee 2017 (VDO personal devices vs Routine care) 1 2018 k 2016 el 2018 k 2016 el 2018 k 2016 el 2018 k 2016 el 2018 k 2016 el 2018 k 2016 el 2018 k 2017 (DD eprsonal devices vs Routine care) - Lee 2017 (VDO personal devices vs Routine care) - Routine c	$\begin{array}{c} \mathbf{BPIT}\\ \mathbf{Mean} & \mathbf{S}\\ 7, \mathbf{S} & 1, \mathbf{S}\\ \mathbf{S}, \mathbf{S} & \mathbf{S}, \mathbf{S}\\ \mathbf{S}, \mathbf{S}, \mathbf{S}\\ \mathbf{S}, \mathbf{S}, \mathbf{S}, \mathbf{S}\\ \mathbf{S}, \mathbf{S}, \mathbf{S}, \mathbf{S}\\ \mathbf{S}, \mathbf{S}, \mathbf{S}, \mathbf{S}\\ \mathbf{S}, \mathbf{S}, \mathbf{S}\\ \mathbf{S}, \mathbf{S}, \mathbf{S}\\ $	Solution         Solution         Solution           D         Total         Total           T         Total         Total	B         B         C           I         Mean         Mean           0         6.29         7.41           2         -2.33         7.44           2         -2.33         7.04           2         -2.33         7.04           2         -3.33         6.33           3         7.04         5.63           4         6.61         7           5         6.31         7.24           5         6.33         6.33           1         7.24         7.45           5         6.31         7.45           5         0         -5.17           7         -4.5         5           9         -5.17           7         -4.5           5         0         -5.17           7         -4.5         5           0         -5.17         -4.21           1         7.9         -5.16           1         7.9         7           1         7.9         7           1         7.9         7           1         7.9         7           1         7.9 <tr< td=""><td>time carr SD 1.83 0 0.74 1.7 1.78 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4</td><td>Total         Wein           144         2           147         2           171         90           2         171           90         2           173         3           141         3           53         2           383         3           668         2           67         2           2333         3           67         2           2333         3           67         2           2333         3           152         2           141         1           153         2           271         2           141         1           135         2           595         2           48         2           500         2           248         2           102         2           247         3           262         2</td><td>Favo Sing Score Std. Mean Difference IV. Random, 95% CI 0, 0, 0, 0, 6 (0.52, 1.00) 0, 0, 25 (0.00, 0.50) Not estimable 0, 25 (0.00, 0.50) Not estimable 0, 0, 24 (0.13, 0.55) 0, 0, 24 (0.13, 0.55) 0, 0, 24 (0.13, 0.55) 0, 0, 24 (0.14, 0.14) 3, 0, 0, 10, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0</td><td>Std. Mean Difference IV, Random, 95% CI</td><td>Risk of Bia         A B C D E         7 2 0 7 7         7 7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7</td></tr<>	time carr SD 1.83 0 0.74 1.7 1.78 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4	Total         Wein           144         2           147         2           171         90           2         171           90         2           173         3           141         3           53         2           383         3           668         2           67         2           2333         3           67         2           2333         3           67         2           2333         3           152         2           141         1           153         2           271         2           141         1           135         2           595         2           48         2           500         2           248         2           102         2           247         3           262         2	Favo Sing Score Std. Mean Difference IV. Random, 95% CI 0, 0, 0, 0, 6 (0.52, 1.00) 0, 0, 25 (0.00, 0.50) Not estimable 0, 25 (0.00, 0.50) Not estimable 0, 0, 24 (0.13, 0.55) 0, 0, 24 (0.13, 0.55) 0, 0, 24 (0.13, 0.55) 0, 0, 24 (0.14, 0.14) 3, 0, 0, 10, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         7 2 0 7 7         7 7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7         7 0 7 7
tal events tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( terogeneity: Tau <sup>2</sup> = 0.00; Chi	$\begin{array}{c} \mathbf{BPIT}\\ \mathbf{Mean} & \mathbf{S}\\ 7, 5, 3 & 1, 3\\ 6, 9 & 1, 8\\ 8, 01\\ -2, 58 & 1, 7, 3 & 1, 3\\ 7, 7 & 1, 7, 1 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1 & 7\\ \mathbf{-3}, 6, 7 & 7 & 7, 7 & 7\\ \mathbf{-3}, 3, 7 & 1, 7 & 7\\ \mathbf{-3}, 3 & 2, 7\\ \mathbf{-4}, 7 & 1, 7 & 7\\ 8, 3 & 0\\ 7, 8 & 1, 1, 6\\ 8 & 1, 0\\ 7, 6 & 1, 1\\ 6, 8 & 1 & 1\\ 6, 4 & 1 & 1 \end{array}$	Sis         D           Totata         0           12         0           17         12:           0         177           12         12:           13         7;           14         144           14         10           14         142:           15         12;           17         33:           18         23:33:           19         13:           33:         22:           12:         12:           13:         32:           14:         13:           13:         32:           14:         13:           13:         32:           14:         13:           12:         10:           12:         12:           12:         12:           11:         12:           14:         12:	(B)         BC           Rou         Rou           Iman         Mean           Iman         Rou	time carr <u>SD</u> 1.83 2.54 0 0.74 1.7 1.78 1.1 1.8 0.9 1.43 1.44 1.47 1.47 1.47 1.47 1.47 1.47 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.43 1.44 1.49 1.96 1.99 1.88 1.99 1.88 1.99 1.88 1.99 1.88 1.99 1.88 1.99 1.88 1.99 1.58 1.99 1.58 1.99 1.57 1.57 1.57 1.57 1.57 1.57 1.57 1.55 1.55 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.55 1.53 1.55 1.53 1.55	Total         Wein           Total         2           121         2           121         2           171         2           173         3           53         2           383         3           668         2           67         2           71         2           2333         3           667         2           271         2           133         3           152         2           14         1           143         3           152         2           14         1           143         3           1355         2           255         2           48         2           80         2           217         3           102         2           247         3           62         2           243         3           62         2	Favo Sing score Std. Mean Difference pht 1V, Random, 95% CI 9% 0.76 (0.52, 1.00) 9% 0.25 (0.00, 0.50) Not estimable 6% -0.24 [-0.55, 0.07] 1% 0.34 (0.13, 0.55] 0% 0.28 [0.05, 0.52] 5% 0.84 [0.49, 1.13] 1% 0.34 (0.49, 1.13] 1% 0.34 (0.49, 1.13] 1% 0.35 (0.24, 0.63] 1% 0.36 [0.22, 0.93] 5% 0.84 [0.49, 1.13] 1% 0.36 [0.15, 1.46] 1% 0.36 [0.15, 1.46] 1% 0.37 [-0.18, 0.42] 3% 0.41 [0.15, 1.46] 1% 0.36 [0.15, 1.46] 1% 0.36 [0.15, 1.46] 1% 0.37 [-0.24, 0.38] 0.17 [-0.24, 0.58] 0.17 [-	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 4( st for overall effect: Z = 7.12 (P < 0.00001) dv or Subgroup k 2018 rely 2014 vera 2007 n 2014 g 2022 (Tolephone vs Routine care) g 2022 (VDO personal devices vs Routine care) g 2023 (Tolephone vs Routine care) g 2024 (SMS vs Routine care) g 2016 g 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2015 (Telephone vs Routine care) 2016 4 2018 k 2015 Hee 2017 (VDO hospital vs Routine care) 12015 k 2016 i 2018 k 2016 i 2020 k 2020 der Zander 2021 der Zander 2021 der Zander 2021 ker 2020 ker 2022 ter 2021 g 2019 (SMS vs Routine care) g 2019 (SMS vs Routine care)	$\begin{array}{c c} \mathbf{BPITT}\\ \hline \mathbf{Mean} & \mathbf{S}\\ \hline 7, 53 & 1.3\\ 5, 99 & 1.8\\ 8, 01\\ -2, 58 & 1.7\\ 7, 31 & 1.7\\ 7, 61 & 1.6\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 7, 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.7\\ 71 & 1.6\\ 71 & 71\\ 71 & \mathbf$	B         D           D         Total           B         137           D         121           T         122           T         122           T         121           T         122           T         121           T         121           T         121           T         121           T         121           T         133           T         77           T         33           T         77           T         33           T         77           T         33           T         76           T         76           T         76           T         76           T         76           T         76           T         78           T         78           T         78           T         78           T         74           T         72           T         74           T         72           T         72	(B)         BC           Iman         Main           1         Main           0         6.29           7         6.43           7         6.31           2         -2.33           7         6.61           2         -5.97           7         6.51           4         6.66           4         6.65           5         6.33           7         -5.17           8 <td< td=""><td>time carr SD - 1.183 1.83 0.74 1.77 1.78 1.1 1.78 1.43 1.95 1.95 1.84 0.9 1.22 1.57 1.53 1.33 1.33 1.31 1.39</td><td>Total         Wein           144         2           147         2           171         2           173         3           141         3           53         2           383         3           668         2           67         2           71         2           2333         3           67         2           71         2           2337         3           152         2           14         1           1353         2           252         3           95         2           48         2           500         2           248         2           102         2           247         3           1027         2           243         3           62         2           62         2           62         2           98         2</td><td>Fave Sing score Std. Mean Difference IV, Random, 95% CI 0, 0, 0, 6 (05, 2, 100) 0, 0, 0, 25 (0,00, 0,50) Not estimable 0, 0, 25 (0,00, 0,50) Not estimable 0, 0, 25 (0,00, 0,50) Not estimable 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0</td><td>Std. Mean Difference IV, Random, 95% CI</td><td>Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         0 0 0 7         7 0 0 7         0 0 0 7</td></td<>	time carr SD - 1.183 1.83 0.74 1.77 1.78 1.1 1.78 1.43 1.95 1.95 1.84 0.9 1.22 1.57 1.53 1.33 1.33 1.31 1.39	Total         Wein           144         2           147         2           171         2           173         3           141         3           53         2           383         3           668         2           67         2           71         2           2333         3           67         2           71         2           2337         3           152         2           14         1           1353         2           252         3           95         2           48         2           500         2           248         2           102         2           247         3           1027         2           243         3           62         2           62         2           62         2           98         2	Fave Sing score Std. Mean Difference IV, Random, 95% CI 0, 0, 0, 6 (05, 2, 100) 0, 0, 0, 25 (0,00, 0,50) Not estimable 0, 0, 25 (0,00, 0,50) Not estimable 0, 0, 25 (0,00, 0,50) Not estimable 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         7 0 0 7         0 0 0 7         7 0 0 7         0 0 0 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 40 st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> .t. 2018 relly 2014 wman 2014 zer 2007 en 2021 ig 2022 (Telephone vs Routine care) ig 2022 (VDO personal devices vs Routine care) ig 2022 (VDO personal devices vs Routine care) n 2014 (SMS vs Routine care) n 2014 (SMS vs Routine care) n 2012 2015 (Cleiphone vs Routine care) 2016 2016 2017 (VDO personal devices vs Routine care) 12014 2018 2018 k 2015 +Lee 2017 (VDO personal devices vs Routine care) 12018 k 2016 ei 2018 k 2016 ei 2018 ai 2018 k 2015 rarara 2017 nomwicz 2022 104 Figure 2021 104 Jigure 2020 Iker 2020 Iker 2021 iker 2021	$\begin{array}{c} \mathbf{BPIT}\\ \mathbf{Mean} & \mathbf{S}\\ 7, 5, 3 & 1, 3\\ 6, 9 & 1, 8\\ 8, 01\\ -2, 58 & 1, 7, 3 & 1, 3\\ 7, 7 & 1, 7, 1 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1\\ 7, 7 & 1 & 7, 7 & 1 & 7\\ \mathbf{-3}, 6, 7 & 7 & 7, 7 & 7\\ \mathbf{-3}, 3, 7 & 1, 7 & 7\\ \mathbf{-3}, 3 & 2, 7\\ \mathbf{-4}, 7 & 1, 7 & 7\\ 8, 3 & 0\\ 7, 8 & 1, 1, 6\\ 8 & 1, 0\\ 7, 6 & 1, 1\\ 6, 8 & 1 & 1\\ 6, 4 & 1 & 1 \end{array}$	B         D           D         Total           P         Total           D         Total           S         Total           D         Total           S	B         B         C           Rou         Mean         6.29         6.29           7         6.43         7.41         2.233           7         6.43         7.41         2.233           2         2.33         7.04         2.63           4         6.66         7.41         2.7           5         6.31         7.45         5.63           1         7.24         7.7         4.55           5         6.33         1.7.24         8.85           0         -5.17         7         -5.50           1         7.92         -5.17         7           5         0         -5.17         7           7         -5.50         -4.21         1           7         -5.17         7         -5.17           0         -5.17         1.7.9         -5.17           1         7.9         -5.17         1.7.9           1         7.9         5.63         7           1         7.9         5.64         5.65           1         7.9         5.78         8           8         5.78         5.78           2 <td>time carr SD 1.183 1.183 2.54 0.74 1.7 1.78 1.1 1.78 1.43 1.43 1.19 1.95 1.88 0.9 1.95 1.88 0.9 1.42 1.43 1.95 1.88 0.9 1.42 1.45 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.39 1.44 1.44 1.44 1.44 1.45 1.57 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.39 1.44 1</td> <td>Total         Wein           144         2           147         2           171         2           173         3           141         3           53         2           383         3           668         2           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           14         1           135         2           252         3           95         2           80         2           217         3           243         3           62         2           247         3           62         2           98         2           243         3           62         2<td>Favo Sing Score Std. Mean Difference IV. Random, 95% CI 960 0.76 (0.52, 1.00) 970 0.25 (0.00, 0.50) Not estimable 0.25 (0.00, 0.50) 100 0.25 (0.00, 0.50</td><td>Std. Mean Difference IV, Random, 95% CI</td><td>Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7</td></td>	time carr SD 1.183 1.183 2.54 0.74 1.7 1.78 1.1 1.78 1.43 1.43 1.19 1.95 1.88 0.9 1.95 1.88 0.9 1.42 1.43 1.95 1.88 0.9 1.42 1.45 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.39 1.44 1.44 1.44 1.44 1.45 1.57 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.39 1.44 1	Total         Wein           144         2           147         2           171         2           173         3           141         3           53         2           383         3           668         2           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           14         1           135         2           252         3           95         2           80         2           217         3           243         3           62         2           247         3           62         2           98         2           243         3           62         2 <td>Favo Sing Score Std. Mean Difference IV. Random, 95% CI 960 0.76 (0.52, 1.00) 970 0.25 (0.00, 0.50) Not estimable 0.25 (0.00, 0.50) 100 0.25 (0.00, 0.50</td> <td>Std. Mean Difference IV, Random, 95% CI</td> <td>Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7</td>	Favo Sing Score Std. Mean Difference IV. Random, 95% CI 960 0.76 (0.52, 1.00) 970 0.25 (0.00, 0.50) Not estimable 0.25 (0.00, 0.50) 100 0.25 (0.00, 0.50	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 40 st for overall effect: Z = 7.12 (P < 0.00001) <b>idy or Subgroup</b> .: 2018 relly 2014 wman 2014 zer 2007 en 2021 ig 2022 (VD opersonal devices vR outine care) ig 2022 (VD opersonal devices vR outine care) ig 2022 (VD opersonal devices vR outine care) n 2014 (SMS vs Routine care) n 2014 (SMS vs Routine care) n 2014 (SMS vs Routine care) n 2012 (VD opersonal devices vs Routine care) n 2012 (VD opersonal devices vs Routine care) 2015 (Cleiphone vs Routine care) 2016 2017 (VD opersonal devices vs Routine care) 12018 4 2018 4 2018 4 2018 4 2018 4 2018 4 2016 4 2017 10 (VD opersonal devices vs Routine care) 12 (VD (VD (VD opersonal devices vs Routine care) 12 (VD (VD (VD (VD (VD (VD (VD (V	$\begin{array}{c} \mathbf{BPIT}\\ \mathbf{Mean} & \mathbf{S}\\ 7,53 & 1.3\\ 6,99 & 1.8\\ 8,01\\ -2,58 & 1.7,61 & 1.6\\ -5,47 & 1.7,71 & 1\\ -7,61 & 1.6\\ -5,47 & 1.7,71 & 1\\ -3,61 & 1.6\\ -5,47 & 1.7,71 & 1\\ -3,61 & 1.7,71 & 1\\ -3,61 & 1.7,71 & 1\\ -3,65 & 1.7,71 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,61 & 1\\ -7,71 & 1\\ 7,12 & 1\\ 7,12 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,11 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1$	Sis         D           Total         12           12         0           17         12           12         0           17         12           17         12           17         12           17         12           11         10           12         10           13         12           13         23           13         22           12         12           13         22           12         12           13         23           13         22           12         12           13         33           14         66           15         84           15         12           16         12           15         12           16         12           16         12           12         12           12         12           12         12           12         12           12         12	(B)         Bcc           Roug         Roug           Iman         Mean           Iman         Roug           Iman	time carr SD 1.183 1.183 2.54 0.74 1.7 1.78 1.1 1.78 1.43 1.43 1.19 1.95 1.88 0.9 1.95 1.88 0.9 1.42 1.43 1.95 1.88 0.9 1.42 1.45 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.39 1.44 1.44 1.44 1.44 1.45 1.57 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.39 1.44 1	Total         Wein           144         2           147         2           171         2           173         3           141         3           53         2           383         3           668         2           67         2           71         2           2333         3           67         2           71         2           2337         3           152         2           14         1           1353         2           252         3           95         2           48         2           500         2           248         2           102         2           247         3           1027         2           243         3           62         2           62         2           62         2           98         2	Favo Sing Score Std. Mean Difference IV. Random, 95% CI 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7
tal events terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 40 terogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.68, df = 40 with constant of the second of the seco	$\begin{array}{c} \mathbf{BPIT}\\ \mathbf{Mean} & \mathbf{S}\\ 7,53 & 1.3\\ 6,99 & 1.8\\ 8,01\\ -2,58 & 1.7,61 & 1.6\\ -5,47 & 1.7,71 & 1\\ -7,61 & 1.6\\ -5,47 & 1.7,71 & 1\\ -3,61 & 1.6\\ -5,47 & 1.7,71 & 1\\ -3,61 & 1.7,71 & 1\\ -3,61 & 1.7,71 & 1\\ -3,65 & 1.7,71 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ 7,71 & 1 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,68 & 1\\ -3,61 & 1\\ -7,71 & 1\\ 7,12 & 1\\ 7,12 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1\\ 7,11 & 1\\ 7,11 & 1\\ 7,12 & 1\\ 7,11 & 1$	Sis         D           Total         12           12         0           17         12           12         0           17         12           17         12           17         12           17         12           11         10           12         10           13         12           13         23           13         22           12         12           13         22           12         12           13         23           13         22           12         12           13         33           14         66           15         84           15         12           16         12           15         12           16         12           16         12           12         12           12         12           12         12           12         12           12         12	(B)         Bcc           Roug         Roug           Iman         Mean           Iman         Roug           Iman	time carr SD 1.183 1.183 2.54 0.74 1.7 1.78 1.1 1.78 1.43 1.43 1.19 1.95 1.88 0.9 1.95 1.88 0.9 1.42 1.43 1.95 1.88 0.9 1.42 1.45 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.39 1.44 1.44 1.44 1.44 1.45 1.57 1.57 1.57 1.57 1.57 1.57 1.53 1.33 1.33 1.33 1.33 1.39 1.44 1	Total         Wein           144         2           147         2           171         2           173         3           141         3           53         2           383         3           668         2           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           71         2           2333         3           67         2           14         1           135         2           252         3           95         2           80         2           217         3           243         3           62         2           247         3           62         2           98         2           243         3           62         2 <td>Favo Sing Score Std. Mean Difference IV. Random, 95% CI 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0</td> <td>Std. Mean Difference IV, Random, 95% CI</td> <td>Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7</td>	Favo Sing Score Std. Mean Difference IV. Random, 95% CI 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0	Std. Mean Difference IV, Random, 95% CI	Risk of Bia         A B C D E         9 7 0 0 7         7 0 0 7

**Figure 5.** Effects of bowel preparation innovative technology interventions (BPITIs) on (**A**) adequate bowel preparation and (**B**) bowel cleansing score. Telephone, telephone re-education; SMS, short message service; VDO hospital, video stream from an on-site hospital device; VDO personal devices, video stream from personal devices.

	BPIT		Adequ Routine		owe	l prep	Daration Risk Ratio	Risk Ratio
Study or Subgroup 1.9.1 Aronchick scale	Events		Events	Total	Weig	ght IV,	Random, 95% CI	IV, Random, 95% Cl
Garg 2016 Lam 2021	34 687	48 983	22 665	46 1010	3.	5% 5%	1.48 [1.04, 2.11] 1.06 [1.00, 1.13]	
Lam 2022 Sharara 2017	286 62	343 80	258 66	342 80	1.	.1% .7%	1.11 [1.02, 1.19] 0.94 [0.80, 1.10]	
Wen 2020 Subtotal (95% CI)	51	70 1524	36	70 1548	0 9.	.8% 7%	1.42 [1.08, 1.85] 1.10 [1.00, 1.21]	•
Total events Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 10.76, df = 4 (	1120 P = 0.03)	l <sup>2</sup> = 639	1047 6					
Test for overall effect: Z = 2.00 (P = 0.05)								
1.9.2 Boston Bowel Preparation Scale (BBPS) Alvarez-Gonzalez 2020	249	303	237	302	3	1%	1.05 [0.97, 1.13]	
Archer 2021 Bearelly 2014	219 110	254 127	205 89	259 121	2	1% 2%	1.09 [1.01, 1.18] 1.18 [1.04, 1.34]	<b>—</b>
Chen 2021 Guo 2020 Jung 2022 (Telephone vs Routine care)	139 112	173 145	125 84	173 148	1	.3% .6% .5%	1.11 [0.99, 1.25] 1.36 [1.15, 1.61]	<u> </u>
Jung 2022 (Telephone vs Routine care) Jung 2022 (VDO personal devices vs Routine care) Keswani 2020	83 96 412	101 104 424	40 40 403	53 53 406	1	.5% .6% .2%	1.09 [0.91, 1.30] 1.22 [1.04, 1.44]	]—
Kim 2014 (SMS vs Routine care)	412 118 125	424 127 126	403 59 59	406 68 68	2	.2% .6% .8%	0.98 [0.96, 1.00] 1.07 [0.96, 1.19] 1.14 [1.04, 1.26]	<u>+_</u>
Kim 2014 (Telephone vs Routine care) Lee 2015 (SMS vs Routine care)	125	126	59 59	67	2	.6% .7% .9%	1.07 [0.97, 1.18] 1.13 [1.03, 1.23]	<u> </u>
Lee 2015 (Telephone vs Routine care) Rice 2016 Seoane 2020	31	42	34 567	50	0	.8%	1.09 [0.84, 1.41]	- <del>-</del>
Shi 2019 Solonowicz 2022	188	200 608	174	200	3	.4% .8%	1.08 [1.01, 1.15] 1.02 [0.97, 1.06]	-
Suzuki 2018 van der Zander 2021	106	227	82 77	223 81	1	.1% .6%	1.27 [1.02, 1.58] 1.04 [0.98, 1.10]	
Veldhuijzen 2020 Walker 2022	261 103	280 111	204 94	217 102		.8% .1%	0.99 [0.95, 1.04] 1.01 [0.93, 1.09]	‡
Walter 2019 Walter 2021	225 227	248 246	199 202	247 243	3.	2% 4%	1.13 [1.05, 1.21] 1.11 [1.04, 1.19]	Ŧ
Wang 2019 (Mobile apps vs Routine care) Wang 2019 (SMS vs Routine care)	114 111	127 128	41 41	62 62	1.	.4% .3%	1.36 [1.13, 1.64] 1.31 [1.08, 1.59]	<u> </u>
Zhang 2018 Subtotal (95% CI)	489	542 5648	469	534 4971	3 67.	.9%	1.03 [0.98, 1.07] 1.08 [1.05, 1.11]	t.
Total events Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 96.09, df = 24	5003 (P < 0.00	001); I <sup>2</sup>	4113 = 75%					
Test for overall effect: Z = 5.21 (P < 0.00001)								
1.9.3 Harefield Cleansing Scale (HCS) Lorenzo-Zúñiga 2015 Subtotal (95% Cl)	108	108 108	146	152 152	4	.0% 0%	1.04 [1.00, 1.08] 1.04 [1.00, 1.08]	r
Total events	108	108	146	132	4.	0%	1.04 [1.00, 1.08]	r i
Heterogeneity: Not applicable Test for overall effect: Z = 2.13 (P = 0.03)								
1.9.4 Ottawa Bowel Preparation Scale (OPBS) leon 2019	71	140	60	141	0	.9%	1.19 [0.93, 1.53]	
Kang 2016 Liu 2014	318 249	387	266 211	383	3.	.1%	1.18 [1.09, 1.28] 1.16 [1.06, 1.27]	
Liu 2018 Pan 2015	215 318	239 387	178 266	237 383	3	.0% .1%	1.20 [1.10, 1.30] 1.18 [1.09, 1.28]	<b></b>
Park 2015 Park 2016	108	136 250	78 198	135 252	1	.6% .2%	1.37 [1.16, 1.63] 1.17 [1.08, 1.26]	
Pillai 2018 Subtotal (95% CI)	30	56 1900	15	48 1879		3%	1.71 [1.06, 2.79] 1.19 [1.15, 1.23]	•
Total events Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.65, df = 7 (P	1538 = 0.58);	<sup>2</sup> = 0%	1272					
Test for overall effect: Z = 9.59 (P < 0.00001)								
1.9.5 Not specified Mahmud 2019	16	19	30	31	1	.2% 2%	0.87 [0.71, 1.07]	-
Subtotal (95% CI) Total events	16	19	30	31	1.	2%	0.87 [0.71, 1.07]	•
Heterogeneity: Not applicable Test for overall effect: Z = 1.33 (P = 0.18)								
Total (95% CI) Total events	7785	9199	6608	8581	100.	0%	1.10 [1.07, 1.13]	•
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 180.49, df = 3 Test for overall effect: Z = 7.09 (P < 0.00001)	9 (P < 0.0		= 78%				0.	2 0.5 1 2 5 Favours [Routine care] Favours [BPITIs]
Test for subgroup differences: Chi <sup>2</sup> = 34.75, df = -					el pr	epara	ation score	rated a produce care) rated as (arris)
Study or Subgroup 2.9.2 Boston Bowel Preparation Scale (BBPS)	BPIT			tine care			Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% CI
Back 2018 Bearelly 2014	7.53 1. 6.99 1.		6.29 6.43	1.83 2.54	144 121	2.9% 2.9%	0.25 [0.00, 0.50]	
Bowman 2014 Chen 2021	8.01 7.61 1.	0 179	7.41 7.04	0 1.7	171 173	3.1%	Not estimable 0.34 [0.13, 0.55]	
Jung 2022 (Telephone vs Routine care) Jung 2022 (VDO personal devices vs Routine care)	7.7 1	.1 101	6.6 6.6	1.1	53 53	2.5%	0.84 [0.49, 1.18]	17-
Keswani 2020 Kim 2014 (SMS vs Routine care) Kim 2014 (Telephone vs Routine care)	8.7 6.76 1. 7.09 1.		8.7 6.31 6.31	0.9 1.43 1.43	406 68 68	3.4% 2.7% 2.7%	0.33 [0.04, 0.63]	
Lam 2022 Lee 2015 (SMS vs Routine care)	8.15 0.		7.98	1.078	333 67	3.3%	0.17 [0.01, 0.32] 0.37 [0.07, 0.67]	
Lee 2015 (Telephone vs Routine care) Lee 2016	7.1 1	.2 125	6.3 7.24	1.4 0.8	67 71	2.6% 2.5%	0.63 [0.32, 0.93] 0.48 [0.14, 0.81]	<u>–</u>
Patel 2018 Rice 2016 Solonowicz 2022	8.67 0. 7 1. 7	18 42	8 6.67 7	1.48 2.22 0	95 50 274	2.5% 2.2%	0.53 [0.21, 0.86] 0.17 [-0.24, 0.58] Not estimable	+
van der Zander 2021 Veldhuitzen 2020		0 329 .9 81	7.9	1.2	274 81 217	2.6%	0.38 [0.06, 0.69] -0.12 [-0.30, 0.06]	
Walker 2022 Walter 2019	8 1. 7.4 1.	05 111 67 248	7.6 6.5	2.02	102 247	2.8%	0.25 [-0.30, 0.52] 0.57 [0.39, 0.75]	- I
Walter 2021 Wang 2019 (Mobile apps vs Routine care)		.1 127	6.7 5.78 5.78	1.56	243 62	3.2% 2.6%	0.57 [0.39, 0.76] 0.87 [0.55, 1.19]	
Wang 2019 (SMS vs Routine care) Xu 2021 Zhang 2018	6.44 1 7.02 1. 7.1 1		5.78 6.45 6.3	1.33 1.91 1.4	62 98 534	2.6% 2.8% 3.4%	0.56 [0.25, 0.87] 0.31 [0.03, 0.59] 0.61 [0.49, 0.74]	
Zhang 2018 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 129.25, df = 22 (P -		4450			3860	64.7%	0.61 [0.49, 0.74] 0.43 [0.31, 0.55]	•
Test for overall effect: Z = 7.11 (P < 0.00001) 2.9.3 Harefield Cleansing Scale (HCS)								
Lorenzo-Zúñiga 2015 Subtotal (95% CI)	17.05 3	2 108 108	16.52	3.1	152 152	2.9% <b>2.9</b> %	0.17 [-0.08, 0.42] 0.17 [-0.08, 0.42]	•
Heterogeneity: Not applicable Test for overall effect: Z = 1.33 (P = 0.18)								
2.9.4 Ottawa Bowel Preparation Scale (OBPS) Jeon 2019	-5.47 1.	4 140	-5.97	1.78	141	3.0%	0.28 [0.05, 0.52]	_
Jeon 2019 Kang 2016 Liu 2014	-3.6 1		-5.97 -4.5 -4.9	1.78 1.8 3.2	141 383 233	3.0%	0.51 [0.37, 0.66]	
Liu 2018 Mi-Hee 2017 (VDO hospital vs Routine care)	-3.05 1	.3 239 1 30	-4.18 -5.17	1.4 1.96	237 14	3.2% 1.3%	0.84 [0.65, 1.02] 0.80 [0.15, 1.46]	
Mi-Hee 2017 (VDO personal devices vs Routine care) Pan 2015 Park 2015	-4.37 1. -3.6 1 -5 8.	.7 387	-5.17 -4.5 -5	1.96 1.8 5.93	14 383 135	1.4% 3.3% 2.9%	0.45 [-0.19, 1.10] 0.51 [0.37, 0.66] 0.00 [-0.24, 0.24]	<u> </u>
Park 2015 Park 2016 Pillai 2018	-3.03 1 -4.77	.9 250 0 56	-4.21 -6.85	1.9 0	252 48	3.2%	0.62 [0.44, 0.80] Not estimable	-
Prakash 2013 Sharara 2017	-3 2. -6.4 1.	2 67	-5 -6.43	2.96 1.84	66 80	2.4%	0.76 [0.41, 1.11] 0.02 [-0.29, 0.33]	+
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.05; Chi <sup>2</sup> = 50.29, df = 10 (P < Test for overall effect: Z = 6.17 (P < 0.00001)	0.00001);	2063   <sup>2</sup> = 80%			1986	29.8%	0.49 [0.33, 0.65]	•
2.9.5 Not specified								
Bytzer 2007 Subtotal (95% CI)	-2.58 1	.3 72 72	-2.33	0.74	90 <b>90</b>	2.6% 2.6%	-0.24 [-0.55, 0.07] -0.24 [-0.55, 0.07]	₹
Heterogeneity: Not applicable Test for overall effect: Z = 1.53 (P = 0.13)								
Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 212.97, df = 35 (P · Test for overall effect: Z = 8.66 (P < 0.00001)	< 0.00001	6693 ; I <sup>2</sup> = 849			6088	100.0%	0.42 [0.33, 0.52]	↓ -4 -2 0 2 4
Test for overall effect: $Z = 8.66$ (P < 0.00001) Test for subgroup differences: $Chi^2 = 20.77$ , df = 3 (P =	0.0001),	<sup>2</sup> = 85.6	6					Favours [Routine care] Favours [BPITIS]

**Figure 6.** Subgroup analyses of the effects of bowel preparation innovative technology interventions (BPITIs) on (**A**) adequate bowel preparation and (**B**) bowel cleansing score by bowel preparation quality scales. Telephone, telephone re-education; SMS, short message service; VDO hospital, video stream from an on-site hospital device; VDO personal devices, video stream from personal devices.

	Summary est	timates*			
	Effect size	(95% CI)	<b>I</b> <sup>2</sup>	No. of studies	No. of participants
Primary outcomes					•
Adequate bowel preparation	OR <sub>adj</sub> 2.92	(1.82 to 4.67)	60%	5	-
Bowel cleansing score	Coef <sub>adj</sub> 0.82	(0.50 to 1.14)	-	1	-
Secondary outcomes					
Polyp detection	RR 1.22	(1.10 to 1.35)	48%	20	7616
Satisfied with intervention	RR 1.38	(1.16 to 1.65)	71%	5	1746
Satisfaction score	SMD 0.62	(0.37 to 0.86)	87%	10	2557

**Table 3.** Meta analyses of the effects of bowel preparation innovative technology interventions (BPITIs) on primary outcomes adjusted for confounding factors and secondary outcomes when compared with routine care. \*Inverse variance method with random effects model.

the quality of bowel preparation which was similar to one of our subgroup analysis findings which observed the effects of mobile applications.

Tian et al., 2021<sup>15</sup> performed a systematic review and network meta-analysis on bowel preparation instructions to deliver bowel preparation information for patients before colonoscopy. This review included 23 RCTs with 10 different bowel preparation technology instructions, including SMS text messaging, telephone calls, newly designed booklets, new visual aids, mobile apps, educational videos, additional explanations, visual aids, and social media applications. Due to the abilities of network meta-analysis, this review is able to compare more than two interventions in a single analysis, determine indirect effects for interventions that have not been directly compared, combine direct and indirect effects which can yield more precise evidence when both direct and indirect effects are available, and rank interventions. In conclusion, they concluded that newly designed booklets, telephone calls, educational videos, and social media applications may promote adherence to bowel preparation. In addition, telephone calls and social media applications may promote adherence to bowel preparation instructions, reduce the risk of adverse events, and increase the polyp detection rate. These findings are in line with our review.

This review included 47 RCTs. The study participants were recruited from 13 countries, mainly from the United States, China, and the Republic of Korea. Only one study was undertaken in a lower-middle-income country, while 35 were conducted in high-income countries. Therefore, healthcare providers and policymakers working in lower-middle-income countries should interpret the findings of this review with caution, considering the potential limitations in terms of resources and accessibility to technology<sup>73,74</sup>. The included studies were published between 2001 to 2022; three RCTs were published prior to 2010, 33 RCTs were published between 2011 to 2020, and 11 RCTs were published after 2020. It is possible that some BPITIs may not be generalisable to the current clinical context. All participants in the included RCTs that reported an indication for colonoscopy were performed colonoscopy for investigation. The study participants were adults or elderly. One trial exclusively included participants who had never undergone a colonoscopy before, but the rest of the trials included participants with or without previous colonoscopy experience.

The risk of bias varied across the included studies. Two-thirds of included studies lacked detailed descriptions of methods for random sequence generation and allocation concealment. Consequently, a substantial proportion of the trials were classified as having unclear risk of bias for the overall risk of bias. Three studies were deemed inadequate random sequence generation because participants were randomly assigned by odd or even colonoscopy date, odd or even medical record number, and the type of participant's smartphone (iOS vs others). Due to the nature of the intervention, where participants and personnel could not be blinded, we classed all trials as having a high risk of performance bias. In this systematic review, the certainty of evidence ranges from very low to moderate. Most of the evidence was downgraded due to the heterogeneity of the included trials. Other factors for downgrading included a lack of clarity or a high risk of bias in the included studies, as well as imprecision (small sample sizes and the limited number of available studies). Potential publication bias was revealed in two of three primary outcomes with ten or more included studies: 1) rate of adherence to dietary restrictions outcome and 2) rate of adequate bowel preparation. We identified 15 trial registrations. The registration dates for these trial registrations range from 2017 to 2021. Uncertainty regarding the status of some trial registrations, whether recruitment is ongoing or complete. As a result, there is a potential risk, as the outcomes of these trials have not been published. The results of this systematic review must therefore be regarded with caution in light of these challenges.

To the best of our knowledge, this is the largest systematic review of bowel preparation innovative technology instructions for colonoscopy. We are aware that bias could occur at any stage during the reviewing process. As a result, we attempt to reduce bias using various methods. A systematic literature search was performed to retrieve all possible RCTs and cluster RCTs in several major electronic databases, as well as the reference list of included trials, regardless of publication status, publication date, and language. Authors of the original study were contacted to confirm unclear information or request additional information. Two review authors independently screened studies, extracted data, assessed the risk of bias, and assessed the certainty of evidence. To minimise errors that may arise during the data extraction process, we created an electronic data extraction form designed explicitly for this review in Microsoft Access, a database management platform. Any differences between the two reviewers in these processes were addressed through discussion, and if necessary, a third reviewer was requested to reach a conclusion. Furthermore, our review determined and presented in greater detail about the characteristics of the included studies, study setting, reported outcomes, and contents of bowel preparation provided in each included study.

However, some obstacles may have had an impact on our results. Due to a variety of bowel preparation innovative technology interventions found in this review, we categorised the interventions into seven categories based on their main characteristics to reduce the number of possible comparisons. There is currently no standard definition for grouping these interventions. This approach may introduce bias into our results. We attempted to make this issue as transparent as possible by providing the description we used in supplemental S2. The range of bowel preparation contents provided in each included study can also lead to varying findings. However, subgroup or meta-regression analyses were not conducted to investigate this factor. Due to the lack of a clinical guideline that specifies the minimal contents that should be provided to patients undergoing colonoscopy, we cannot classify interventions based on this factor. Publication bias, a high risk of selection bias due to the nature of this intervention in which participants and health personnel could not be blinded, and substantial heterogeneity identified in almost all meta-analyses are other biases that should be taken into account in this study. One of the sources of heterogeneity was types of bowel preparation quality scale. The included studies used the following four validated bowel preparation scales to evaluate the quality of bowel preparation: (1) the Boston Bowel Preparation Scale (BBPS), (2) the Ottawa Bowel Preparation Scale (OBPS), (3) the Aronchick scale (AC), and (4) the Harefield Cleansing Scale (HCS). Thus, the gold standard bowel preparation and adherence to instruction tools should be developed for reliable measurement.

In a real-world clinical setting, some BPITIs may not be suitable for all participants. Those with low digital health literacy and cognitive impairment, for instance, may be less likely to benefit from advanced technology platforms. Therefore, once developing and implementing innovative technology platforms to enhance the quality of bowel preparation, it is necessary to consider the characteristic of participants, particularly their needs, preferences, and ability to access innovative technology platforms. In addition, well-designed RCTs using validated tools to evaluate outcomes are still required to reaffirm our findings, and the results should be strictly reported by following the CONSORT guidelines. Future studies might determine the effects of innovative interventions regarding bowel preparation to reduce patients' pre-procedural anxiety and increase user satisfaction. We did not find studies examining the cost-effectiveness of these technologies. Therefore, further studies regarding the cost-effectiveness of these platforms might be required.

#### Conclusion

This meta-analysis provides substantial evidence that bowel preparation innovative technology instructions may slightly improve overall adherence to instructions, adequate bowel preparation, and quality of bowel preparation score. The findings should be interpreted with caution due to the low and moderate certainty of evidence and heterogeneity among the included studies since the types of intervention and types of bowel preparation quality scale.

### Data availability

All data generated or analysed during this study are included in this published article or the supplementary file.

Received: 7 December 2022; Accepted: 14 June 2023 Published online: 04 July 2023

#### References

- Keum, N. N. & Giovannucci, E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16, 713–732 (2019).
- 2. WHO—World Health Organization. GLOBOCAN—Colorectal cancer incidence in the world. *Glob. Cancer Obs.* **419**, 1–2 (2020).
- Guren, M. G. The global challenge of colorectal cancer. *Lancet Gastroenterol. Hepatol.* 4, 894–895 (2019).
   Low, E. E. et al. Risk factors for early-onset colorectal cancer. *Gastroenterology* 159, 492-501.e7 (2020).
- Kaminski, M. F. Robertson, D. J., Senore, C. & Rex, D. K. Optimizing the quality of colorectal cancer screening worldwide. *Gastroenterology* 158, 404–417 (2020).
- Johnson, D. A. et al. Optimizing adequacy of bowel cleansing for colonoscopy: Recommendations from the US multi-society task force on colorectal cancer. Gastroenterology 147, 903–924 (2014).
- 7. Clark, B. T., Rustagi, T. & Laine, L. What level of bowel prep quality requires early repeat colonoscopy: Systematic review and meta-analysis of the impact of preparation quality on adenoma detection rate. *Am. J. Gastroenterol.* **109**, 1714–1723 (2014).
- Mahmood, S., Farooqui, S. M. & Madhoun, M. F. Predictors of inadequate bowel preparation for colonoscopy: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 30, 819–826 (2018).
- 9. Chokshi, R. V., Hovis, C. E., Hollander, T., Early, D. S. & Wang, J. S. Prevalence of missed adenomas in patients with inadequate bowel preparation on screening colonoscopy. *Gastrointest. Endosc.* **75**, 1197–1203 (2012).
- Kurlander, J. E. et al. How efficacious are patient education interventions to improve bowel preparation for colonoscopy? A systematic review. PLoS ONE 11, e0164442 (2016).
- 11. Arslanca, G. & Aygün, M. Effect of nurse-performed enhanced patient education on colonoscopy bowel preparation quality. *Rev. Lat. Am. Enfermagem* **30**, e3626 (2022).
- 12. Walter, B. *et al.* Smartphone application to reinforce education increases high-quality preparation for colorectal cancer screening colonoscopies in a randomized trial. *Clin. Gastroenterol. Hepatol.* **19**, 331-338.e5 (2021).
- Zhao, Y., Xie, F., Bai, X., Yang, A. & Wu, D. Effect of educational virtual reality videos on improving bowel preparation quality and satisfaction of outpatients undergoing colonoscopy. *Turk. J. Gastroenterol.* 30, S253–S254 (2019).
- 14. Bizri, M. E., Sheikh, M. E., Lee, G. E. & Sewitch, M. J. Mobile health technologies supporting colonoscopy preparation: A systematic review and meta-analysis of randomized controlled trials. *PLoS ONE* **16**, 1–19 (2021).
- Tian, X. et al. Comparative effectiveness of enhanced patient instructions for bowel preparation before colonoscopy: Network meta-analysis of 23 randomized controlled trials. J. Med. Internet Res. 23, e19915 (2021).

- Kang, X. et al. Delivery of instructions via mobile social media app increases quality of bowel preparation. Clin. Gastroenterol. Hepatol. 14, 429-435.e3 (2016).
- 17. Veldhuijzen, G. *et al.* Computer-based patient education is non-inferior to nurse counselling prior to colonoscopy: A multicenter randomized controlled trial. *Endoscopy* 53, 254–263 (2021).
- 18. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). (Cochrane, 2022).
- Page, M. J. *et al.* The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Syst. Rev.* 10, 89 (2021).
   Haddaway, N. R., Collins, A. M., Coughlin, D. & Kirk, S. The role of google scholar in evidence reviews and its applicability to grey
- literature searching. PLoS ONE 10, e0138237 (2015).
  21. Higgins, J., Altman, D. & Sterne, J. Chapter 8: Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions version 5.2 (updated June 2017) (eds Higgins, J. et al.) (Cochrane, 2017).
- Schünemann, H. J. et al. Chapter 15: Interpreting results and drawing conclusions. In Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022) (eds Higgins, J. et al.) (Cochrane, 2022).
- Deeks JJ, Higgins JPT, A. D. (editors) on behalf of & the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. in *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* (eds. Deeks, J. J., Higgins, J. P., Altman, D. G. & the Cochrane Statistical Methods Group.) (Cochrane, 2011).
- 24. Deeks, J., Higgins, J. & Altman, D. Chapter 10: Analysing data and undertaking meta-analyses. In *Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)* (eds Higgins, J. et al.) (Cochrane, 2022).
- Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration, https://training.cochrane.org/onlinelearning/core-software-cochrane-reviews/revman/revman-5-download (2020).
- Wan, X., Wang, W., Liu, J. & Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 14, 135 (2014).
- Higgins, J. P. T., Eldridge, S. & Li, T. Chapter 23: Including variants on randomized trials. In Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022) (eds Higgins, J. P. et al.) (Cochrane, 2022).
- GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. (The GRADE Working Group, 2013).
- Alvarez-Gonzalez, M. A. *et al.* Educational nurse-led telephone intervention shortly before colonoscopy as a salvage strategy after previous bowel preparation failure: A multicenter randomized trial. *Endoscopy* 52, 1026–1035 (2020).
- Archer, T. *et al.* P8 Does an educational video improve bowel preparation in patients first colonoscopy? A UK multi-centre RCT. *Gut* A45.1-A45 (2021). https://doi.org/10.1136/gutjnl-2020-bsgcampus.83
- Back, S. Y. et al. Impact of patient audiovisual re-education via a smartphone on the quality of bowel preparation before colonoscopy: A single-blinded randomized study. Gastrointest. Endosc. 87, 789-799.e4 (2018).
- Bearelly, D. et al. Instructional video improves the quality of bowel preparation for colonoscopy: Presidential poster. Am. J. Gastroenterol. 109, S599 (2014).
- Bowman, E. A., Benson, M. E., Hourigan, J., Selby, L. & Caldera, F. 844 Double blinded randomized control trial to evaluate if an educational video can improve bowel preparation. *Gastrointest. Endosc.* 79, AB180–AB181 (2014).
- 34. Bytzer, P. & Lindeberg, B. Impact of an information video before colonoscopy on patient satisfaction and anxiety—A randomized trial. *Endoscopy* **39**, 710–714 (2007).
- Chen, G. et al. Educating outpatients for bowel preparation before colonoscopy using conventional methods vs virtual reality videos plus conventional methods: A randomized clinical trial. JAMA Netw. Open 4, e2135576 (2021).
- Garg, S. et al. Improved bowel preparation with multimedia education in a predominantly African-American population: A randomized study. Diagn. Ther. Endosc. 2016 (2016).
- 37. Guo, B. *et al.* Improving the quality of bowel preparation through an app for inpatients undergoing colonoscopy: A randomized controlled trial. *J. Adv. Nurs.* **76**, 1037–1045 (2020).
- Jeon, S. C. et al. Effect of sending educational video clips via smartphone mobile messenger on bowel preparation before colonoscopy. Clin. Endosc. 52, 53–58 (2019).
- Jung, D. H. et al. Combination of enhanced instructions improve quality of bowel preparation: A prospective, colonoscopistblinded, randomized, controlled study. Dis. Colon Rectum 65, 117–124 (2022).
- 40. Keswani, R. N. *et al.* Colonoscopy education delivered via the patient portal does not improve adherence to scheduled first-time screening colonoscopy. *Endosc. Int. Open* **08**, E401–E406 (2020).
- Kim, E., Cho, K., Park, K., Choi, E. & Lee, S. Comparison of impact of reinforced education between telephone and short message service on the quality of bowel preparation: A prospective, colonoscopist-blinded, randomized, controlled study. United Eur. Gastroenterol. J. 2, A42 (2014).
- 42. Lam, T. Y. T. et al. Short message service reminders reduce outpatient colonoscopy nonattendance rate: A randomized controlled study. J. Gastroenterol. Hepatol. 36, 1044–1050 (2021).
- Lam, T. Y. T. et al. Nurse-led reinforced education by mobile messenger improves the quality of bowel preparation of colonoscopy in a population-based colorectal cancer screening program: A randomized controlled trial. Int. J. Nurs. Stud. 133, 104301 (2022).
- 44. Lee, H., Lee, S. & Lee, Y. The impact of patient education with smartphone application on the quality of bowel preparation for screening colonoscopy. United Eur. Gastroenterol. J. 4, A661-662 (2016).
- Lee, Y. J. et al. Impact of reinforced education by telephone and short message service on the quality of bowel preparation: A randomized controlled study. Endoscopy 47, 1018–1027 (2015).
- 46. Liu, C., Song, X. & Hao, H. Educational video followed by retelling bowel preparation process to improve colonoscopy bowel preparation quality: A prospective nursing intervention study. *Med. Sci. Monit.* 24, 6029–6037 (2018).
- Liu, X. et al. Telephone-based re-education on the day before colonoscopy improves the quality of bowel preparation and the polyp detection rate: A prospective, colonoscopist-blinded, randomised, controlled study. Gut 63, 125–130 (2014).
- Lorenzo-Zúňiga, V., Moreno De Vega, V., Marín, I., Barberá, M. & Boix, J. Improving the quality of colonoscopy bowel preparation using a smart phone application: A randomized trial. *Dig. Endosc.* 27, 590–595 (2015).
- 49. Mahmud, N. *et al.* Effect of text messaging on bowel preparation and appointment attendance for outpatient colonoscopy: A randomized clinical trial. *JAMA Netw. Open* **4**, e2034553 (2021).
- 50. Mahmud, N. *et al.* An automated text message navigation program improves the show rate for outpatient colonoscopy. *Heal. Educ. Behav.* **46**, 942–946 (2019).
- 51. Mi-Hee, C. & Jun-Ah, S. Effects of video assisted education using smartphone on bowel preparation for colonoscopy. J. Korean Acad. Fundam. Nurs. 24, 60–71 (2017).
- Pan, Y., Kang, X., Luo, H. & Guo, X. 436 Instruction delivered by mobile social media app increases quality of bowel preparation and adenoma detection rate: A prospective, colonoscopist-blinded, randomised, controlled study. *Gastrointest. Endosc.* 81, AB146 (2015).
- Park, J.-S. et al. A randomized controlled trial of an educational video to improve quality of bowel preparation for colonoscopy. BMC Gastroenterol. 16, 64 (2016).
- 54. Park, J. et al. The effectiveness of short message service to assure the preparation-to-colonoscopy interval before bowel preparation for colonoscopy. Gastroenterol. Res. Pract. 2015 (2015).
- 55. Patel, V., Patel, H., Cavanagh, Y., Debari, V. & Baddoura, W. The role of mobile phone text message reminders in adherence to bowel preparation for outpatient colonoscopies. *Gastroenterology* **155**, e45–e46 (2018).

- Pearson, S., Maddern, G. J. & Hewett, P. Interacting effects of preoperative information and patient choice in adaptation to colonoscopy. Dis. Colon Rectum 48, 2047–2054 (2005).
- Pillai, A., Menon, R., Oustecky, D. & Ahmad, A. Educational colonoscopy video enhances bowel preparation quality and comprehension in an inner city population. J. Clin. Gastroenterol. 52, 515–518 (2018).
- Prakash, S. R. *et al.* Improving the quality of colonoscopy bowel preparation using an educational video. *Can. J. Gastroenterol.* 27, 696–700 (2013).
- Rice, S. C. et al. Video on diet before outpatient colonoscopy does not improve quality of bowel preparation: A prospective, randomized, controlled trial. Am. J. Gastroenterol. 111, 1564–1571 (2016).
- 60. Seoane, A. *et al.* Evaluation of an educational telephone intervention strategy to improve non-screening colonoscopy attendance: A randomized controlled trial. *World J. Gastroenterol.* **26**, 7568–7583 (2020).
- Sharara, A. I. et al. A customized mobile application in colonoscopy preparation: A randomized controlled trial. Clin. Transl. Gastroenterol. 8, e211 (2017).
- Shaw, M. J., Beebe, T. J., Tomshine, P. A., Adlis, S. A. & Cass, O. W. A randomized, controlled trial of interactive, multimedia software for patient colonoscopy education. J. Clin. Gastroenterol. 32, 142–147 (2001).
- 63. Shi, H. *et al.* Impact of patient education on bowel preparation quality before water-aided colonoscopy. *World Chin. J. Dig.* 27, 632–636 (2019).
- 64. Solonowicz, O. et al. Digital navigation improves no-show rates and bowel preparation quality for patients undergoing colonoscopy: A randomized controlled quality improvement study. J. Clin. Gastroenterol. 56, 166–172 (2022).
- 65. Suzuki, M. M. *et al.* A21 Randomized prospective study: Impact of the patient education website on the quality of outpatient bowel preparation for colonoscopy. *J. Can. Assoc. Gastroenterol.* **1**, 38–39 (2018).
- 66. Van Der Zander, Q. E. W. *et al.* Effects of a personalized smartphone app on bowel preparation quality: Randomized controlled trial. *JMIR mHealth uHealth* **9** (2021).
- 67. Walker, T. B., Hengehold, T. A., Garza, K., Rogers, B. D. & Early, D. An interactive video educational tool does not improve the quality of bowel preparation for colonoscopy: A randomized controlled study. *Dig. Sci.* **67**, 2347–2357 (2022).
- Walter, B. *et al.* Improving the quality and acceptance of colonoscopy preparation by reinforced patient education with short message service: Results from a randomized, multicenter study (PERICLES-II). *Gastrointest. Endosc.* 89, 506-513.e4 (2019).
- Wang, S. L. *et al.* Effect of WeChat and short message service on bowel preparation: An endoscopist-blinded, randomized controlled trial. *Eur. J. Gastroenterol. Hepatol.* **31**, 170–177 (2019).
   Wang, M. C. *et al.* Smarthhone education improves embergesement, howel preparation, and esticfaction with care in patients received.
- Wen, M. C. *et al.* Smartphone education improves embarrassment, bowel preparation, and satisfaction with care in patients receiving colonoscopy: A randomized controlled trail. *Medicine (Baltimore)* 99, e23102 (2020).
- 71. Xu, F. *et al.* Educational video on the WeChat platform can effectively improve the quality of bowel preparation: A prospective, randomized, controlled study. *Gastroenterol. Nurs.* **44**, 47–51 (2021).
- 72. Zhang, Q. X. *et al.* Effect of education by messaging software on the quality of bowel preparation for colonoscopy. *Chin. Med. J.* (*Engl*) **131**, 1750–1752 (2018).
- McCool, J., Dobson, R., Whittaker, R. & Paton, C. Mobile health (mHealth) in low- and middle-income countries. Annu. Rev. Public Health 43, 525-539 (2022).
- 74. Abaza, H. & Marschollek, M. mHealth application areas and technology combinations\*. A comparison of literature from high and low/middle income countries. *Methods Inf. Med.* 56, e105–e122 (2017).

# Author contributions

P.W. and O.S. conceived the idea for this study. P.W., O.S. and S.R. developed the protocol, developed the search strategy, performed screening, review of full-texts, data extraction, and risk of bias assessments. S.R. performed the database search and developed an electronic data collection form. S.R. and P.W. performed the meta-analysis. S.R. and O.S. graded the certainty of evidence and created the summary of findings table. P.W. reviewed the certainty of evidence. P.W., O.S. and S.R. wrote the first manuscript draft and all authors made substantial contributions, including interpretations of the findings and critical revisions of the manuscript. Before submission, the final version of the manuscript was approved by all authors.

# Funding

This research project was financially supported by the Faculty of Nursing, Khon Kaen University, Thailand.

# **Competing interests**

The authors declare no competing interests.

# Additional information

**Supplementary Information** The online version contains supplementary material available at https://doi.org/ 10.1038/s41598-023-37044-w.

Correspondence and requests for materials should be addressed to O.S.

Reprints and permissions information is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023